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Take home message: 
Written by Europeans for Europeans, the minimum dataset and manual for lung cancer 
services will help to improve standards for our patients. 
 
Abstract 
Introduction 
The European Respiratory Society taskforce for harmonised standards for lung cancer 
registration and lung cancer services in Europe recognised the need to create a single 
dataset for use in pan-European data collection, and a manual of standards for European 
lung cancer services. 
 
Methods 
Existing national and international datasets were reviewed with the results of a survey of 
clinical data collection on lung cancer in 35 European countries.  These two different sources 
of evidence were considered by the multidisciplinary taskforce.  A similar process was 
followed for the manual of lung cancer services where existing guidelines and national or 
international recommendations for lung cancer services were used to develop a manual of 
standards for services in Europe. 
 
Results 
Essential and minimum datasets for lung cancer registration were developed to enable all 
countries to collect the same essential data and some to collect data with greater detail. A 
manual specifying standards for lung cancer services in Europe was developed. 
 
Conclusion 
Despite the wide variation in the socio-political landscape across Europe, the ERS is 
determined to encourage the delivery of high quality lung cancer care.  The manual of lung 
cancer services and minimum dataset for lung cancer registration will both support this 
aspiration. 
 
Introduction 
Lung cancer is the second most common cancer in men and women in Europe and the 
commonest cause of cancer related death (1).  Europe accounts for a quarter of all lung 
cancer deaths globally despite representing an eighth of the worlds’ population (2).  Recent 
advances in techniques for diagnosis, staging and treatment have seen a modest 
improvement in outcomes and there is hope that further developments in molecular 
targeted treatments and immunotherapy, as well as potential combination treatments and 
the expected implementation of low radiation dose CT screening will improve outcomes 
further (3). However, improvements in clinical services vary greatly across Europe due to a 
variety of organisational, economic and socio-political factors. To help drive the adoption of 
best clinical practice that is delivered more equitably, an agreed service specification is 
needed and agreement on the metrics by which the service can be measured. This requires 
a description of the standards for lung cancer services and a uniform cancer registration 
system to measure the activity. 
In 2015, the European Respiratory Society (ERS) approved a taskforce to create a pan-
European thoracic oncology dataset and develop internationally agreed standards for 
European thoracic oncology centres. The membership of the taskforce was derived from a 
previously successful taskforce on quality management in lung cancer and hence includes a 
multidisciplinary group with a keen interest in the development of harmonised international 
standards.  The two main aims of this group were to develop: 
1. a pan-European dataset; 
2. a manual of standards for lung cancer services in Europe. 
Lung cancer registration in Europe: the need for a pan European dataset 
Cancer data collection in Europe began in the 1950’s with the establishment of cancer 
registries.  However, it was not until the 1990’s that they were widespread enough to allow 
meaningful comparative research to be done.  The EUROCARE series of large scale 
publications has demonstrated the variation in epidemiological features and outcomes in a 
large number of European countries (4, 5).  These publications have sparked interest from 
the public and politicians alike and they have been the catalyst for many developments at 
the national and international level to improve the outcomes for individuals with cancer.  
The number of cancer registries involved in EUROCARE studies has grown, and the level of 
population coverage improved; but there remain large parts of Europe that are not 
accounted for in these studies (6).  Data items and their definitions are not universally 
agreed, and so comparisons cannot always be standardised.  Furthermore, few registries 
collect sufficient clinical details at the individual patient level to support meaningful 
comparisons of outcome within and between countries. 
The European Union’s strategy against cancer has focussed on the importance of cancer 
registration.  It has funded several initiatives including the European Action Against Cancer 
Programme (1985-2008); the European Partnership for Action Against Cancer (EPAAC) 
(2009-2014) (7) and the EU Cancer Control Joint Action (CANCON) (8).  The European 
Network Cancer Registries (ENCR) were set up in 1990 as a joint venture with several other 
international cancer research groups to promote the quality of cancer registration across 
Europe, and the use of these data for clinical and public health research.  The ENCR has 
published a minimal dataset for cancer registries as well as an optional dataset (9).  These 
are generic for every cancer rather than being lung cancer specific. 
Lung cancer services in Europe: the need for harmonised international standards 
Europe has a diverse healthcare structure generated by diversity in social, political and 
economic factors. However, in thoracic oncology, the aim of the healthcare system is to 
provide the best standard of care to provide patients with the best outcomes. In general, 
countries have a combination of large centres, usually based in large hospitals with a 
concentration of expertise and technology, and smaller healthcare providers, with less 
equipment and less comprehensive services. Some countries have primary care services in 
addition that play a crucial role throughout the lung cancer pathway. A previous ERS 
taskforce report described the differences in the healthcare infrastructure for 38 European 
countries (10). The diversity across Europe has undoubtedly contributed to the variation in 
healthcare outcomes and agreement on the standards centres should adopt is one way to 
mitigate this effect.
Methods 
Group composition 
The taskforce was chaired by Anna Rich and Torsten Blum with a further 25 members from 
nine countries around Europe.  All members have a specialist interest in lung cancer, and 
represent different aspects of the multi-disciplinary team: pathology, pulmonology, 
radiation oncology, medical oncology, thoracic surgery, palliative care, a lung cancer 
specialist nurse, and a medical statistician.  Patients views were represented through the 
European Lung Foundation’s (ELF’s) lung cancer patient advisory group (PAG). 
 
Conflicts of interest 
All taskforce members declared and signed conflict of interest statements at the beginning 
of the project and updated them at project finalisation.  
 
Working methods 
The taskforce met at face-to-face meetings held at the ERS congress in Amsterdam in 
September 2015.  The aims and objectives of the project were discussed and agreed, and 
the proposal for two workstreams, lead by Anna Rich (minimum dataset) and Torsten Blum 
(manual for lung cancer services) was ratified.  Further face-to-face meetings were held in 
London in May 2016, the ERS congress in London in September 2016, and then in London 
March 2017.  A final face-to-face meeting was held at the congress in Milan in September 
2017 when the final report was discussed in detail.  Conference calls and email 
correspondence were also used to discuss and amend the detail within the minimum 
dataset and the manual of lung cancer services as they were developed.  Agreement within 
the taskforce group achieved >90% prior to inclusion within the report. 
 
- Review of existing datasets 
Datasets in use or in development were reviewed before and during meetings of the 
taskforce. This included the work from an allied project (11) as well as national datasets 
from countries represented on the taskforce. Supplement 3.1 reports the datasets 
reviewed, and key facts regarding their development. The aim was to understand the 
similarities and differences in data collected and to derive a harmonised dataset that would 
encompass, as far as possible, existing data collected as well as extending this to a minimum 
dataset.  Existing datasets from ENCR and the International Consortium for Health Outcome 
Measures (ICHOM) were used as reference datasets (9, 12). These were chosen for their 
comprehensiveness and because they were developed by international groups. However, 
the taskforce identified that these datasets were too detailed and ambitious to be applied 
as harmonised standards in Europe where a more pragmatic approach was needed. 
Membership of the taskforce included professionals who have considerable experience in 
developing and implementing national audits. This expertise was used to make realistic 
proposals for a European dataset.  The data items were chosen on the basis of consensus 
opinion, with a majority of >90% agreement. 
 
- Evidence search and review of existing manuals  
Members of the taskforce performed a narrative search of existing manuals for lung cancer 
services including relevant websites or printed publications of related international societies 
and other stakeholders, and national level publications accessible by taskforce members 
(see Supplement 3.3).  Given that a systematic search on the national level was beyond the 
means of this taskforce, the group accepted a potential selection bias based on the 
limitation to only those European countries represented on the taskforce. 
 
Subsequently, Dr. Torsten Blum browsed repeatedly during the course of this taskforce 
through the websites of the named international societies and other stakeholders for 
substantial online or referenced printed publications. Retrieved evidence from this narrative 
search as well as reports identified by other taskforce members were amalgamated by Dr. 
Blum and then discussed during taskforce meetings. All searches on the international level 
were last updated by him in November 2017. Detailed results are provided in Supplement 
3.3. 
 
The previous ERS taskforce on quality management in lung cancer care has revealed that 
there were more than 150 lung cancer guidelines worldwide, and more than 80 within 
Europe (10).  There was significant variation in the quality of these guidelines: in terms of 
the underlying evidence used, the specific aspects of the lung cancer pathway being 
addressed and the publication date.  Only a minority of these guidelines addressed in any 
meaningful way, the detail with respect to infrastructure and pathway processes, to inform 
our aspired manual of standards for lung cancer services. 
 
The taskforce has not performed systematic evidence searches in medical data bases on its 
own, but used relevant results from a GRADE based systematic review of the literature on 
quality management in lung cancer with a focus on the impact of defined lung cancer 
services.  This was the subject of a parallel ERS taskforce that will be published in full 
separately.  Overall, published material was found to be very limited and of low quality.  
An agreed list of standards for lung cancer services in Europe was developed during 
taskforce meetings and interim discussion.  The recommended manual of standards for lung 
cancer services is based on a review of available evidence and is complemented by the 
inclusion of patient perspective as well as the clinical experience of the taskforce members.  
 
European Lung Foundation’s (ELF’s) Patient Advisory Group 
ELF’s lung cancer patient advisory group (PAG) was established to support a range of 
research activities relating to lung cancer.  The PAG is made up of people who have received 
a diagnosis of lung cancer (either undergoing treatment or survivors), caregivers of people 
with lung cancer, and representatives of lung cancer patient organisations.  Every member 
responded to an advert on the ELF website and were interviewed informally by phone or 
skype before being accepted onto the PAG. The PAG allows individuals to self-select which 
projects they can most usefully support, based on their experience and interests, and also 
allows them to withdraw at any time if health issues arise. 
The taskforce regarded it as essential to create a dataset and manual that were meaningful 
to patients and ELF staff member, Jeanette Boyd, was invited to attend taskforce meetings 
and to facilitate the gathering of views from PAG members regarding the development of 
both the pan-European dataset and manual for lung cancer services.  Five members 
provided feedback for the dataset (4 patients and 1 patient organisation representative 
from Czech Republic, Italy and UK) and 4 members provided feedback for the manual of 
lung cancer services (2 patients, 1 caregiver and 1 patient organisation representative from 
Denmark, Ireland, Poland and the UK). Views were gathered by sharing documentation by 
email and requesting feedback. Jeanette Boyd collated and analysed the feedback using a 
qualitative approach and presented this to the taskforce for consideration. In addition, Dr 
Torsten Blum conducted semi-structured telephone interviews with PAG members for 
feedback relating to the manual of lung cancer services. 
 
Manuscript preparation 
The taskforce final report was written by Dr Anna Rich and Dr Torsten Blum, with editing 
and some modification provided by Prof David Baldwin.  Prof Micheal Peake was invited to 
write the subsection regarding the National Lung Cancer Audit of England and Wales, as an 
external co-author.  The paper was then circulated to all members of the taskforce and 
revisions made by Dr Rich.  The statement paper and supplements were reviewed, edited 
and approved by all members of the taskforce before submission. 
 
Glossary of Terms 
Abbreviation Definition 
.csv Comma separated values 
.xml Extensible markup language 
COSD Cancer Outcomes and Services Dataset 
CT Computed tomography 
DLCG Danish Lung Cancer Group 
DLCR Danish Lung Cancer Registry 
DNPR Danish National Patient Registry 
DPR Danish Pathology Register 
ECOG Eastern Cooperative Oncology Group 
ELF European Lung Foundation 
ENCR European Network Cancer Registries 
EORTC European Organisation for Research and Treatment of Cancer 
ERS European Respiratory Society 
EU European Union 
GRADE Grading of Recommendations Assessment, Development and Evaluation 
HAS Haute Autorite de la Sante (France) 
IASLC International Association for the Study of Lung Cancer 
ICD International Classification of Disease 
ICHOM International Consortium for Health Outcome Measures 
IFCT French Intergroup of Thoracic Oncology 
INCa Institut National du Cancer (France) 
LCNS Lung Cancer Nurse Specialist 
LUCADA Lung Cancer Data 
MDT Multi-Disciplinary Team 
NCI National Cancer Institute (United States of America) 
NCRAS National Cancer Registration and Analysis Service 
NHS National Health Service 
NLCA National Lung Cancer Audit 
OECI Organisation of European Cancer Institutes 
PAG Patient Advisory Group 
PCR Pathological Confirmation Rate 
PET-CT Positron Emission Tomography-Computed Tomography 
PIN Personal Identification Number 
PROMs Patient Reported Outcome Measures 
PS Performance Status 
QoL Quality of Life 
RCP Royal College of Physicians 
SES Socio-Economic Status 
SNOMED Systematized Nomenclature of Medicine 
WHO World Health Organisation 
 
 
Part 1. Development of a pan-European lung cancer dataset 
 
Two national lung cancer datasets stood out as exemplars of data completeness and use of 
data to drive improvement in services and outcomes; they are described below. 
Drivers, development and implementation of two national lung cancer audit programmes: 
Denmark and England 
Drivers 
The two main drivers for the development of both of these well-established audit 
programmes were i) preliminary comparative data, in the 1990s, suggesting poorer 
outcomes than in other countries; and ii) evidence for unwarranted variation in clinical 
practice. EUROCARE-1 reported 5 year survival in lung cancer in England and Denmark as 
being below 8% (4).  This prompted the Royal College of Physicians of London, with funds 
provided by the English Government, to sponsor a snapshot audit (13). This audit, involved 
52 hospitals between 1995 and 1996, showed large variations in the care of lung cancer 
patients and led to efforts to establish a longer term, population-based lung cancer audit 
programme. In Denmark, similar variations were apparent. The healthcare system was 
organised so that diagnostics and treatment was provided by a large number of hospital 
departments with very different approaches to the disease.  The Danish Lung Cancer Group 
(DLCG) was formed with the primary aim of improving the clinical management and survival 
of Danish lung cancer patients.  A secondary aim was to produce a platform for lung cancer 
research.  The DLCG produced national guidelines for the management of lung cancer (14) 
and adopted a strategy to implement the guidelines and concurrently monitor the 
implementation by reporting to a national registry – The Danish Lung Cancer Registry 
(DLCR). 
  
Development and implementation 
The Danish Lung Cancer Registry 
The DLCR started in 2000 and now contains data on around 70,000 patients.  Between 2000 
and 2012, inclusion of patients relied on clinicians identifying and reporting patients to the 
DLCR, but since 2013, patients are identified from the first diagnostic codes for lung cancer 
in the Danish National Patient Registry (DNPR). The latter helped improve data 
completeness and reduce the workload for clinicians. Participation has since become 
mandatory by law, so data completeness is now more than 95% of new cases. The basic 
database is derived from the DNPR and the Danish Pathology Register (DPR) and includes 
procedures and treatment. This is supplemented and validated online by clinicians to form 
the DLCR. All departments involved in the diagnosis and treatment of lung cancer in 
Denmark are responsible for the validation and supplementation of data (15). 
The database contains demographic and patient characteristics, details of treatment 
including surgery, type and duration of chemotherapy and type and duration of radiation.  
Vital status is derived monthly from the Danish Civil Registration System and age at 
diagnosis confirmed from the personal identification number (PIN).  During the 18 years of 
data collection in the DLCR major improvements in treatment outcomes have been 
recorded (16).  DLCR has developed a number of indicators using scientific evidence and the 
national guideline recommendation. The indicators are reported monthly and annually to all 
participating departments, hospitals and healthcare authorities.  A comprehensive system of 
audits ensures that differences in quality measures and failure to meet standards are 
evaluated. 
A number of publications based on the DLCR have appeared since 2009, documenting the 
effects of a national registry.  The two major lessons that have been learned are firstly that 
high data quality and completeness is essential to ensure participation of clinicians in 
working with data and results from the database.  Meaningful audit depends on the 
accuracy and credibility of data; only once clinicians were convinced of this, was it possible 
to shift the focus from data quality to the findings.  Secondly, involvement of hospital and 
regional management in the process of implementation is important to facilitate the 
changes in services and clinical practice that are recommended from the findings of the 
audit (17).  Centralization in Denmark is traditionally met with resistance from local 
stakeholders, and the involvement of management has played a central role.  The DLCR has 
shown that regional differences have decreased as the number of departments involved in 
treating lung cancer patients has halved (17). 
The DLCG has in 2017 formulated an ambitious goal to double survival from lung cancer 
before 2030 (18) and it is widely recognized that the DLCR plays a crucial part in achieving 
this goal. 
The National Lung Cancer Audit (UK) 
In 1999, a multi-disciplinary ‘Intercollegiate’ Lung Cancer Group published: ‘Lung Cancer: A 
core dataset’ (19).  From the outset, the aim was to achieve as near total population 
coverage as possible; and in order to make achieving this more likely, the size of the dataset 
was limited.  It has evolved over the years (20), but the number of fields requiring 
completion for any one patient is usually less than 50. 
In 2004 the English Government, through the National Clinical and Patient Outcomes 
Programme, which funds over 30 National Clinical Audits in England, began to support the 
central functions of a national lung cancer audit programme.  Wales joined the programme 
in 2006, and collated data from Scotland and Northern Ireland have been included in 
reports whenever possible. 
The principles of the audit and findings were regularly presented at regional and national 
multi-professional clinical meetings to encourage clinical engagement, which was initially 
limited.  However, despite non-mandatory participation, the proportion of patients 
captured by the audit rose from 40% in 2005 to 100% in 2009 and has remained at that level 
since.  In 2009 participation was mandated by formal contract between the Department of 
Health and provider hospitals. 
A bespoke database was developed (called LUCADA - LUng CAncer DAta) in one of the 
National Health Service’s (NHS) central computing systems, allowing direct, secure data 
entry of individual patient data or compiled grouped data on multiple patients as .csv or 
.xml formatted files.  This system also allowed each hospital to see its own grouped data at 
any time with comparative, anonymised data from other hospitals. 
Multi-Disciplinary Teams (MDT) were well established (21) and these teams were used as 
the focus for data collection, some appointing data coordinators or building the work into 
the roles of MDT co-ordinators or even Lung Cancer Nurse Specialists.  Each local hospital 
developed or purchased its own software for data collection, though by the late 2000s over 
80% were using one of two systems.  Data completeness improved rapidly, for example, 
completeness of performance status and stage data fields reached >80% by 2009 (22) and 
have exceeded 90% since (23). 
The first annual report was published and made available to the general public in 2006 (24). 
The hospitals were identified along with their activity, data completeness and outcomes. 
This lead to a great deal of press activity and complaints from hospitals that their data were 
not accurate, but this served as a vital driver behind the rapid improvements in participation 
and data completeness that followed.  Reports and anonymised spreadsheets of data are 
now available to the public via the RCP website (25). 
Data quality and completeness are major issues for any large scale population-based audit. 
Co-morbidity proved to be difficult to collect, both incomplete and inconsistent.  As with the 
DLCR, the Charlson Index is used, derived from in-patient diagnostic codes.  Until recently 
detailed data on combination therapies and second and subsequent lines of treatment has 
been limited; this is now collected through two other databases, one for radiotherapy and 
one for systemic therapy.  Palliative care, primary care and Patient-Reported Outcome 
Measures (PROMS) have so far not been routinely linked to the NLCA. 
The NLCA has changed the culture of the Thoracic Oncology community in the UK; raising 
awareness of local and regional activity, patterns of care and outcomes of patients with lung 
cancer and mesothelioma.  Surgical resection rates have doubled since the audit began and 
less dramatic improvements have been seen in a wide range of other indicators of high 
quality care (25).  The 1 and 5 year survival rates have increased in recent years (26) and 
appear to parallel the improvements in treatment rates.  There have been a large number of 
peer-reviewed publications that have emerged using the NLCA data and these have been 
influential in recommendations for the commissioning of services.  In 2014 the NLCA team 
at the Royal College of Physicians began working directly with the National Cancer 
Registration and Analysis Service (NCRAS) in Public Health England and to a large extent now 
uses data collected in the national Cancer Outcomes and Services Dataset (COSD) as the 
basis of their analyses and reports. 
Patient perspectives on the development of a pan-European lung cancer dataset 
The European Lung Foundation’s (ELF’s) lung cancer patient advisory group (PAG) was asked 
specific questions about the development of a pan-European dataset and the views outlined 
below are from five individuals with experience of lung cancer from the Czech Republic, Italy 
and the United Kingdom. 
Value of a pan-European dataset 
PAG members were in agreement that the implementation of a lung cancer dataset across 
Europe would be particularly useful in: 
 developing and monitoring diagnostic standards; 
 developing and monitoring standards of care in lung cancer;  
 assisting evidence-based analysis of data across countries; 
 establishing what treatments work and for whom. 
Patient access to data would be of interest and value to patients as a way to understand 
more about their condition and what could be viewed as usual/unusual in comparison with 
others. This would give individuals a useful comparator to discuss their condition with 
clinicians. In light of this, patient access to the data should be considered as part of any 
dataset development. 
Gathering data 
It was noted that patients could provide valuable input in defining the relevant importance 
of different quality of life (QoL) data, and the considerations to be aware of when collecting 
these.  Patients felt it was important for QoL data to be collected verbally, directly from 
patients, to ensure consistency, and to identify patterns across the pathway which could 
then lead to identification of relevant support where appropriate.  A crucial factor for the 
successful gathering of information from the patient is the level of trust that exists between 
clinician and patient.  The QoL questionnaire EORTC QLQ-C30 was identified by the Task 
Force as a possible resource, as this is already a standardised tool in use (27).  The PAG 
members thought that some of the questions were relevant, but that a subset of these 
questions might be more effective. 
PAG members suggested that there could be a beneficial role for caregivers, nurses and 
hospice staff in helping gathering QoL information and assisting patients, especially at times 
of high stress and anxiety.  They identified these times as often being at  the point of 
diagnosis and/or when patients may not have much energy, for example during 
chemotherapy, or when receiving palliative care.  This will vary with each individual and 
further discussions would be beneficial to ensure data were both sensitively and effectively 
gathered.  Patient reported outcomes have demonstrated positive impact on treatment 
outcomes and their use is expected to increase in the future (28).  Specific 
recommendations on PROs are not dealt with in this recommendation. 
The PAG thought QoL data collection would be most valuable at diagnosis, post primary 
treatment (3 months) and at the end of primary treatment (6 months).  Several PAG 
members also felt that it would be helpful to gather data after 12 months.  It was also 
suggested that collecting QoL from patients at the end of a 5 year recurrence-free-follow-up 
could be valuable in sharing hope among patients. 
PAG members recommended that the gathering of co-morbidity data should be patient-led 
and clinician reported.  The data should emerge from a discussion and agreement between 
the clinician and patient.  This would have the additional advantage of patients being better 
informed about potential co-morbidities and provide opportunities for pre-agreement with 
their clinician about what to do should symptoms appear, potentially leading to lower 
patient anxiety in the long term. 
Implementation topics of importance to patients 
Implementation topics were identified that were important to patients including: informed 
patient consent; data protection and data security; data use and patient knowledge of how 
it is used; and information about clinical trial involvement.  Providing personalised data 
summaries with pan-European comparison would also be a valued option. 
ELF would recommend that patient representatives are fully involved in future discussions 
about dataset development to ensure that all patient issues have been considered and any 
potential challenges addressed before any future roll-out across Europe. 
Recommendations for a pan-European dataset for lung cancer registration 
The proposed pan-European dataset for lung cancer registration can be divided into four 
sections, with data items relating to:  basic patient features, tumour details, extended 
patient features, and details of the lung cancer pathway and process.  The tables include 
data items which should be mandatory in the minimum dataset (marked in black) as well 
those which are desirable (marked in blue).  For practical utility, all four tables are also listed 
in Supplement 1. Data items in the minimum dataset were felt to be essential for basic 
epidemiology required to evaluate key clinical outcome measures, and are already collected 
in a majority of European countries (11).  The minimum dataset for lung cancer (including 
tracheal cancer) is for all patients with an International Classification of Disease (ICD v10) 
code of c33, or c34. 
Basic patient features 
Table 1 illustrates data items for basic patient features.  A record of ethnicity is important 
for several reasons.  There is evidence of significant variations in the prevalence of somatic 
mutations in adenocarcinoma of the lung based on ethnicity (29, 30).  There is also evidence 
of variation in the route to accessing healthcare services based on patient ethnicity (31-33).  
However, it is difficult to find one coding system for ethnicity that would capture the needs 
of every country in Europe.  The ICHOM dataset definition (12) states that individual 
countries should determine the definition, and therefore this data item is not suitable for 
cross country comparison.  So, the taskforce concluded that it was not possible to propose 
one list of ethnicity codes that would be relevant for every country in Europe (an example of 
a coding system is shown in supplement 3.2).  The educational level of an individual was 
chosen as a surrogate for the socio-economic status.  Some countries have well established 
linkage between registries or independent lung cancer audit programmes and census data 
which allow them to stratify an individual’s socio-economic status (SES).  However, these are 
the minority, and although socio-economic status is a very important indicator of access to 
healthcare generally, as well as key clinical outcomes in thoracic oncology (34-36), a 
compromise was agreed.  The taskforce adopted a simple outline of educational level 
achieved based on ICHOM (primary, secondary or tertiary) (12). It was recognised that there 
is wide variation in the level of educational status achieved in different countries, and that it 
is not an ideal surrogate for SES but despite this limitation it was thought educational level 
would be a data item which could be captured. 
Five data items relate to the diagnosis of lung cancer, how it was made with the inclusion of 
pertinent dates; these will be powerful points of reference when interpreting the lung 
cancer pathway and processes within each country or between countries.  Delays in referral 
to a lung cancer specialist have been proposed as a reason for differences in outcomes so 
the date of referral to a lung cancer specialist is included.  It is acknowledged that the route 
to a lung cancer specialist varies across Europe, and it often does not involve a primary care 
physician (10).  There is a hierarchical basis to the date of diagnosis, which is taken from the 
ENCR minimum dataset for Cancer Registries (9).  The date of the final pathology report, 
reflects the need to identify delays in obtaining a complete pathological diagnosis 
consequent upon increasingly complex processing.  The mode of presentation is an essential 
data item as it is known to influence prognosis. 
The basis of diagnosis (clinical/radiological or pathological) is crucial because of the 
association with prognosis: a more precise identification of the denominator for the whole 
cohort, allows international comparisons to reduce selection bias. Comparisons must use 
the same denominator because cohorts that only include patients with pathological 
confirmation do not include those patients with an often worse prognosis, who are 
diagnosed purely on the basis of a high level of clinical suspicion; such patients are often too 
unwell or too frail to undergo further tests.  There is evidence that the likelihood of 
obtaining pathological confirmation in individuals believed to have lung cancer is affected by 
several factors.  These include: age (37), their social-economic status (38), and performance 
status (PS) (39). Equally, factors relating to the lung cancer service could account for 
variation in pathological confirmation rates (PCRs), and hence the recommendation for 
agreed standards amongst lung cancer services in Europe (see part 2).  Internationally there 
is no agreed PCR, but research from the National Lung Cancer Audit of England, found that 
higher PCRs were most strongly associated with survival in patients with stage I/II disease 
who had a PS of 0-1 (40). Thus, a stratified approach to pathological confirmation, based on 
clinical features, was suggested rather than a single benchmark figure for PCR.  The basis of 
diagnosis is the same as that defined by ICHOM (12). 
Tumour details 
Data that specify details of the tumour (see table 2) are essential for international 
comparisons because of the strong influence on prognosis, type of treatment offered and 
prediction of treatment response.  The pathological subtype is vital, and we know that 
different countries within Europe use different systems.  The majority use the International 
Classification Diseases -Oncology-3rd edition which incorporates all subtypes according to 
the current 2015 World Health Organization Classification of Lung Tumors (41) including the 
new lung adenocarcinoma classification originally proposed by IASLC, ATS and ERS (42). 
However Denmark uses Systematized Nomenclature of Medicine (SNOMED).  The taskforce 
recommends that data are entered into the system using whichever classification is 
standard practice within each country.  Retrieval of specific pathological sub-types could 
then be reconstructed with automated algorithms.  For those countries without a specific 
pathological classification system, we have created a small but clinically relevant list of 
pathological subtypes.  The field of molecular analysis is expected to expand in the future 
and so there is a need to have a data collection system which can include new definitions as 
clinical practice changes.  These changes could be incorporated during a revision 
programme every two years, in order to balance clinical development with practical utility. 
Stage of disease at diagnosis is compliant with the International Association for the Study of 
Lung Cancer (IASLC) staging system (43).  The basis of the stage reflects access to certain 
procedures as well as national guidelines for diagnosing lung cancer, so there are data fields 
to record which investigations have been performed prior to the formation of a ‘final pre-
treatment clinical stage’.  The version of the staging system (7 or 8) is selected first, and 
then the individual T, N and M stage is entered.  However, further details about tumour size, 
the number and location of nodes and metastases then follow.  Sub-classification of the 
extent of N2 disease is included as part of the desirable dataset, which could then be used 
to categorise the patient cohort based on either the Robinson classification (44) or the IASLC 
staging project (assuming N1 disease is also subclassified-see table) (45).  This level of detail 
from a pan-European cohort of individuals with lung cancer, will allow comprehensive and 
very detailed analysis of the prognostic value of the current IASLC staging system. 
Extended patient features 
Table 3 illustrates the extended patient features.  The main data item in this section is 
Performance Status (PS) of the individual at the time of diagnosis with lung cancer.  The 
Eastern Cooperative Oncology Group (ECOG) system (46) for recording this feature (also 
known as the World Health Organistion PS) is the most widely used method, although there 
is evidence that PS is only routinely collected in less than a third of European countries (11).  
It is paramount that this becomes a routine patient feature collected in all registries or audit 
programmes given the important role it plays in predicting outcome (39, 47-50). 
The subsequent data items would allow detailed evaluation of the clinical outcomes from 
lung cancer within and between countries.  The majority of European countries do not 
collect many of these, and it would take significant investment and political support to 
achieve this.  Co-morbidity is a fundamental part of the evaluation of a patient prior to 
making a treatment plan for them, and there is good evidence of the influence of co-
morbidity on outcome (51-54).  The Charlson Index was developed in the late 1970’s and 
validated on a cohort of patients with breast cancer (55).  It has subsequently been used in 
numerous studies, but it has limited functionality given the complexity of the score, the lack 
of clarity regarding severity of co-morbid disease, and the out-of-date weighting given to 
HIV/AIDS.  The ACE-27 score is an alternative model used by some to quantify co-morbid 
disease (56), and some countries record specific co-morbid diseases, but the list is variable 
(11).  Therefore the ICHOM list of co-morbid diseases (based on Sangha et al (57)) is 
recommended, but should be derived from the medical notes after consultation between 
the  clinician and the patient.  It was hoped this would ensure accurate recording of all 
known co-morbidities.  The EORTC QLQ-C30 patient completed questionnaire is 
recommended for QoL (27).  This is based on the fact it is a validated research tool (58), 
although our patient group felt only a subset of the questions were relevant.  This should be 
recorded at diagnosis, after completion of first line treatment, and at six months post-
diagnosis.  This may be difficult to achieve but quality of life for patients is a fundamental 
outcome measure, often neglected; and members of our patient advisory group felt that 
ideally we would also collect QoL data at 12 months and after 5 year survival, where 
applicable.  A revised QoL questionnaire is in development, which incorporates elements of 
the QLQ-C30 with specific reference to side-effects from medical treatments including 
chemotherapy and targeted therapies (59). 
Lung cancer pathway/outcomes 
The final section of the European recommended minimum dataset relates to aspects of the 
lung cancer pathway, specifically the outcomes in terms of treatment and survival (see table 
4).  Patients in some countries have identified how important contact with a lung cancer 
nurse specialist (LCNS) is because they provide significant support to patients and their 
families throughout the lung cancer pathway.  Although there is no accepted international 
definition the taskforce suggests the following: a LCNS is one whose primary role is to meet 
individuals with lung cancer at diagnosis, sometimes before, and then to provide support for 
the patient and their family in terms of education, access to benefits, liaising with primary 
care physicians, and emotional support. The role may include other duties such as 
administering chemotherapy, although this does not, on its own meet the essential 
elements of holistic care described above. 
Treatment data items are shown in table 4 and provide a comprehensive list of treatment 
options and associated secondary questions, which would not apply to all.  In order for 
meaningful analysis of lung cancer outcomes to take place, and the influence of treatment 
modalities on survival to be assessed, every effort must be made to capture all relevant 
information. 
Part 2. Manual of standards for lung cancer services in Europe 
 
Publications defining lung cancer service specification had variable content. Four broad 
areas were identified that distinguished them:  
 geographic scope (international, national or regional setting); 
 comprehensiveness of care (comprehensive cancer services, lung cancer specific 
services and those that provide only selected diagnostic or treatment modalities) 
 publishing body, such as national or international healthcare authorities or medical 
societies, insurance companies or other non-governmental bodies reimbursing costs 
of care, foundations, or a combination of these bodies; 
 the time point and up-to-dateness of publication. 
No international initiatives could be identified which defined standards of care specifically 
for the entire lung cancer pathway although there are two examples of relatively 
comprehensive cancer care service definitions on the European level. These are the 
European Society for Medical Oncology Designated Centres of Integrated Oncology and 
Palliative Care accreditation programme, initiated in 2003 (60) and the Organisation of 
European Cancer Institutes (OECI) Accreditation and Designation-Programme, revised in 
2015 (61). Several international medical societies have published statement papers on 
standards for selected parts of the lung cancer pathway which are listed in table 5. 
The United States National Cancer Institute (NCI) established the first successful 
comprehensive cancer centre-programme in 1971, supported by the National Cancer Act. 
There are now 69 NCI-designated (Comprehensive) Cancer Centers, all of whom have a 
focus on basic, clinical and population based research (62). This has been reviewed in 
relation to developing centres in Europe to support, primarily, research(63). 
The Bonnie J. Addario Lung Cancer Foundation have established their own foundation-based 
‘Centre of Excellence Program’ currently encompassing 17 community hospitals as well as 
17 Addario Lung Cancer Medical Institute hospitals in the United States of America and 3 in 
Europe, (Paris, France; Torino, Italy; and Barcelona, Spain) (64) 
There are a number of other approaches which have been taken in order to formalise the 
lung cancer pathway within European countries, and these are described in the paragraphs 
below. 
UK 
In 1995, the report by Calman and Hine, a ‘Policy Framework for Commissioning Cancer 
Services’, set the basic standards for cancer services in England and Wales including multi-
disciplinary team working as a core element of cancer services (65). Since then, the NHS has 
further developed and regularly updated standards of cancer centre-based care in the UK, 
and standards have been monitored through a national peer review process and the NLCA 
(19, 20, 22). Furthermore, a ‘national optimal clinical pathway for suspected and confirmed 
lung cancer: from referral to treatment’ has been published (66).  Recently, Cancer Research 
UK has named one ‘Lung Cancer Centres of Excellence’, jointly based in London and 
Manchester, whose aim is to develop and promote high-level lung cancer research (67). 
Denmark 
In Denmark, as mentioned above, the DLCG with the national lung cancer registry and the 
national lung cancer guideline programme in collaboration with national healthcare 
authorities catalyzed a process of continuous improvement of lung cancer care which 
amongst others has implicated a re-organization with centralization of Danish lung cancer 
services (17).  Supplement 3.4 depicts the lung cancer service in the region of Southern 
Denmark. 
France 
In France, there is a national taskforce against cancer which has developed following three 
national ‘Cancer plans’ (68).  The first ‘Cancer plan’, launched by president Chirac (2003-
2007) set the basis of a national strategy for multidisciplinary management of cancer.  It 
legalized the compulsory multidisciplinary discussion of each individual cancer patient.  
Multidisciplinary teams (MDTs) are organized according to organ or system, and within 
thoracic oncology, pleural mesothelioma and thymic epithelial tumours fall within rare 
tumour boards (national), rather than the lung MDT.  The MDT discussion must lead to a 
consensual personalized treatment plan, which is a written document given to the patient 
during a structured consultation, and a nurse co-ordinator is also present offering 
psychological or social support if required.  The plan is also sent to the general practitioner, 
and all corresponding doctors. 
The first ‘Cancer plan’ also elaborated on accreditation of units caring for patients with 
cancer, and in particular on surgical units.  A surgical unit should host at least 2 surgeons, 
have access to an intensive care unit, to an endoscopy suite, and frozen section analysis 
should be available on site.  Minimum thresholds have been set per organ, which result in a 
minimal caseload of 20 major resections per surgeon (respectively 30 cases per unit, given 
some surgeons work on more than just cancer). 
The ministry of health created a National Institute of Cancer (Institut National du Cancer, 
INCa) in 2005, which coordinates research and treatment in oncology.  In this role INCa 
publishes an annual report and collaborates with 25 regional oncology networks, who 
coordinate screening and treatment at the regional level.  INCa is also connected to the 
Higher Authority of Health (Haute Autorité de la Santé, HAS), which is in charge of editing 
guidelines and quality control.  Finally, INCa has accredited and coordinates 8 inter-groups 
for clinical research including the French Intergroup of Thoracic Oncology (IFCT). 
Two subsequent ‘Cancer plans’ have been launched by president Sarkozy (2009-2013) and 
Hollande (2014-2019).  The third Cancer plan is an ambitious document (69) which aims to 
improve treatment, but in addition to act before diagnosis (prevention, screening) and after 
treatment (follow-up, social re-integration). 
Germany 
In 2008, the German Cancer Society in collaboration with the German Respiratory Society 
and the German Society of Thoracic Surgery initiated a certification programme for lung 
cancer centres as part of the German National Cancer Plan. In September 2016 there were 
44 certified lung cancer centres in Germany and 2 in Switzerland. The certification process is 
composed: 
 an annual updated parameter manual with mandatory and recommended elements 
of structure, process and outcome data which are used for self-assessment and 
subsequent external validation; 
 annual visits to the respective lung cancer service by trained external specialists; 
 an extensive evaluation of the results by an independent institute, 
 followed by a final evaluation (70, 71). 
The German parameter manual contains 10 chapters covering mainly medical aspects of the 
lung cancer pathway. Multi-professional/disciplinary working is encouraged and there are 
specific mandatory standards for centres. These include diagnosing and treating ≥200 new 
pathologically confirmed lung cancer patients/year, ≥75 anatomical lung cancer 
resections/year, and recording performance indicators such as 30-day mortality after 
anatomical lung cancer resections ≤5%, and proportion of broncho-/angioplastic resections 
on all anatomical resections ≥10 %. Clinical lung cancer registration and follow-up data 
collection is mandatory in every certified lung cancer centre and their close linkage to the 
newly established clinical cancer registries of the 16 German Federal States is promoted (70, 
71). The process has seen improvements in multidisciplinary working. 
Only 33% of all new cases of lung cancer in 2016 were covered by certified lung cancer 
centres. The main obstacles for broader implementation are the mandatory thresholds for 
new cases and surgical resections (70, 71). Other medical societies in Germany have 
established independent certification programmes related to lung cancer care (i.e. the 
‘Oncological Centres’ of the German Society for Haematology and Medical Oncology, and 
the ‘Thoracic Centres’ of the German Society of Thoracic Surgery, the latter initiative 
appraising both benign and malignant disease) (72, 73). 
Overview of the development of the manual of standards for lung cancer services in 
Europe  
The taskforce group agreed on the following scope and core principles for development of 
the parameter manual of European standards for lung cancer services: 
1. The primary target audience of the parameter manual is professionals involved in lung 
cancer care in Europe. The standards will also be important for lung cancer patients, their 
carers, and other stakeholders in lung cancer care. 
2. The main aim is to harmonize and improve standards of lung cancer care throughout 
Europe. Multi-disciplinary team work and patient-centred care are central. 
3. The parameter manual is composed of two sections covering (i) Infrastructure and 
organization of the lung cancer service and (ii) standards for lung cancer services at each 
stage of the lung cancer pathway. 
4. Standards are divided into essential and advanced. Essential standards are defined as 
criteria which are mandatory for the lung cancer service to fulfill basic standards of effective 
care. Advanced standards are defined as those that go beyond that which is essential to 
provide higher-quality lung cancer care. 
5. The underlying evidence base for the essential and advanced standards was graded into 
three levels: (i) ‘Guideline’: wherever possible, generally accepted clinical lung cancer 
guideline recommendations were used to conclude standards of the infrastructure or 
pathway for lung cancer services (i. e. the guideline recommendation ‘Lung cancer patients 
who are potentially suitable for treatment with curative intent should be offered PET-CT 
before treatment’ led to the essential standard in this manual ‘The lung cancer service must 
provide or have access to PET-CT’; (ii) ‘Literature review and assessment’: these denoted 
standards were based on an assessment of the available non-guideline literature; (iii) ‘Good 
practice’: in the absence of any guideline recommendations or other literature, taskforce 
members and patient representatives used their clinical experience to reach conclusions 
about what consitutes good clinical practice for certain standards. 
6. Acknowledging that differences in terminology can lead to differences in interpretation 
across Europe, a glossary for the terminology is provided in supplement 2. 
The Patient Advisory Group (PAG) formulated patient priorities in lung cancer care which 
have been previously published in an ELF report (74). These patient priorities comprise 
proper patient involvement and provision of relevant and understandable information 
needed for decision-making, quantitative and qualitative improvement of patient-
professional contacts throughout the lung cancer pathway, better involvement of other 
professions, especially lung cancer nurses, supervision and psychological support for doctors 
and other professionals, specific communication training for professionals, and better 
linkage between lung cancer services. 
 
Recommendations for a Pan-European manual of standards for lung cancer 
services 
Organization of the Lung Cancer Service 
This first section addresses the relevant organizational aspects of the lung cancer service as 
a whole (see Supplement 2).  Although a multi-disciplinary network environment is an 
essential requirement, it was agreed that the specific membership should be determined 
according to the local and/or national setting.  Advanced standards have been formulated to 
encourage lung cancer services with a full range of diagnostic and/or treatment facilities to 
offer these to partner organisations.  It is important to note that there is no one 
infrastructure that every service should adopt.  Every aspect of the lung cancer pathway 
should be available to the individual patient, but the delivery of this may vary at the local 
level.A real-life example of a multi-site lung cancer service from Denmark is included in 
Supplement 3.4. 
The standards for Patient- and Carer-centred Care were elaborated by the members of the 
PAG. The evidence base for this is limited, although not strictly necessary where a patient 
expert group has commented and where there are several national lung cancer guidelines 
recommending shared decision making on the basis of easy to access and understand 
information (75). 
The taskforce identified further essential standards in a lung cancer service which relate to: 
 adherence to evidence-based care, with use of regularly updated guidelines; 
 access to specialized care; 
 timeliness of care; 
 documentation, accessibility and provision of patient and carer-related information; 
 communication and environment for communication;  
 education for healthcare professionals, patients and carers (one example would be 
the Thoracic Oncology HERMES syllabus and curriculum (76-80)); 
 clinical cancer registration; 
 quality assurance, quality improvement, risk management; 
 collaboration with external healthcare professionals and other external stakeholders 
by the lung cancer service. 
The utilization of the proposed pan-European dataset for lung cancer registration is 
recommended as an advanced standard. Advanced collaborative measures have been 
proposed by the taskforce group to facilitate local, regional, national and international 
networking. 
Lung Cancer Pathway 
The second section of the manual encompasses the entire lung cancer pathway within the 
lung cancer service from diagnosis, through treatment, follow-up, relapse and end of life or 
survivorship (see Supplement 2). The underlying international and national guidelines which 
provide recommendations related to most of the essential and advanced standards within 
this section are listed in table 5. 
Cross-pathway care is included in this section. This is often important to ensure that 
patients experience is maximised when care is needed from services outside the lung cancer 
pathway which may include emergency care, intensive care, and services for specific 
symptom management.  Palliative care is included here but it is noted that this should be 
provided throughout the entire pathway (see figure 1) (81). 
Pre-existing statement papers and recommendations issued by other international medical 
societies have been reviewed and incorporated into the manual of standards where 
appropriate.  These include: imaging (82), fitness for diagnostics and radical therapy (83), 
thoracic surgery (84), radiotherapy (85-93), and palliative care (94).  Due to limited evidence 
and heterogeneity among and within European countries, the taskforce group was unable to 
define standards for individual or institutional volumes of care and timeliness/waiting times.  
 
The future: implementation of harmonised standards in Europe 
The proposed pan-European lung cancer dataset and manual of standards for lung cancer 
services provides the opportunity to harmonise registration and quality of services in 
Europe.  A previous ERS taskforce showed marked inequalities in lung cancer care among 
and within European countries (10), and importantly established a network of interested 
clinicians, who are ready to be involved with the implementation of these standards.  Thus, 
we have so far identified variation, reviewed guidelines and this paper defines both a pan-
European dataset and standards for lung cancer services. 
Our proposed standards for lung cancer services and lung cancer registration comprise two 
essential parts of a lung cancer guideline cycle based on the model originally introduced by 
the European Commission in 2004 (see figure 2) (95, 96). Given the surplus of existing lung 
cancer guidelines, and as a consequence, substantial waste of human and financial 
resources, it is imperative that multiple uncoordinated initiatives on the international, 
national and regional level should be avoided. Therefore, the ERS will seek collaborations on 
a par with other leading European societies to define joint pan-European standards for lung 
cancer services and lung cancer registration based on this statement paper as well as multi-
professional, patient-centred lung cancer guidelines. This would also save valuable 
resources on the national or regional level. Given the rapidly evolving field of lung cancer 
care, these standards will need to be revised on a regular basis to ensure their relevance 
and efficacy. 
Dissemination and implementation of these standards is vital. Although there are some 
examples of service improvement initiated through involvement of individual members of 
the taskforce, it is now important to actively manage the process of improving services, care 
and outcomes throughout Europe.  This may be done using methods of service 
improvement that have been used in individual countries using our established network. 
Peer review is one such established method.  This allows individuals and teams to review 
each other’s services, with reference to agreed standards (97). In the European setting this 
process could really drive up standards of care. The peer review process will involve 
clinicians visiting and evaluating services that may be very different, with the opportunity to 
suggest some profoundly helpful changes and to learn from one another.  Following a 
recent feasibility project benchmarking lung cancer services in Glasgow and Berlin, the ERS 
will endeavour to support peer review projects on a pan-European scale. 
In summary, the taskforces of the ERS Thoracic Oncology Assembly have so far provided 
important information about the variation in lung cancer care in a range of European 
countries with marked differences in social and political backgrounds. The next phase is to 
start the process of service improvement, whilst acknowledging the variable resources 
available in individual countries.  It is envisaged that this current taskforce project will set 
the basis for a multi-national, multi-society and patient-centred lung cancer care 
collaboration with the clear aim to improve and harmonize standards of lung cancer care for 
the benefit of patients, their carers and professionals alike. 
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Supplement 1 
Pan-European Lung Cancer Dataset 
Basic patient features 
Data item Definition Detailed definition 
Date of birth dd/mm/yyy
y 
 
Sex Male or 
female 
1=male 
2=female 
999=undisclosed/unknown 
Country of 
registration 
ISO-3166 2 letter code 
Education level Numerical 
value 
(ICHOM) 
Indicate highest level of education completed 
0=None 
1=Primary 
2=Secondary 
3=Tertiary (college, university) 
999=Don’t know 
Date of referral dd/mm/yyy
y 
Date on which referral made with respect to potential lung cancer. 
 
This could include, self-referral, primary to secondary care, within secondary care 
 
Option for missing/unknown. 
Date of diagnosis dd/mm/yyy
y 
Date the first histopathology/cytology sample was taken which confirmed malignancy, 
 
If date of histopathology sample not available then index date based on following criteria in 
descending order. (as per IARC) 
1. Date of first histological or cytological confirmation of this malignancy (with the exception of 
histology or cytology at autopsy). This date should be, in the following order: 
a) date when the specimen was taken (biopsy) 
b) date of receipt by pathologist 
c) date of the pathology report 
2. Date of admission to hospital because of this malignancy. 
3. When evaluated at an outpatient clinic only: date of first consultation at the out-patient clinic 
because of this malignancy. 
4. Date of diagnosis other than 1,2 or 3. 
5. Date of death, if no information is available other than the fact that the patient died of a 
malignancy. 
6. Date of death, if the malignancy is discovered at autopsy. 
Date of final 
pathology report 
dd/mm/yyy
y 
Date of final pathology report to include molecular analysis where appropriate 
 
Option for missing/unknown. 
Mode of 
presentation 
How was 
lung cancer 
first 
suspected? 
 
Numerical 
value 
0=screening 
1=symptoms 
2=incidental finding 
3=other (free text box to specify) 
999=don’t know 
Basis of diagnosis Numerical 
value 
(ICHOM) 
1=Clinical 
2=Histology 
3=Cytology 
999=unknown 
 Clinical Diagnosis made before death with or without diagnostic techniques (e.g. X-rays, endoscopy, 
imaging, ultrasound, exploratory surgery) but without a tissue diagnosis 
 Histology Histological examination of tissue from the primary tumour or metastasis, including all cutting and 
bone marrow biopsies. Also includes autopsy specimens. 
 Cytology Examination of cells whether from a primary or secondary site, including fluids aspirated using 
endoscopes or needles. Also including microscopic examination of peripheral blood films and 
trephine bone marrow aspirates 
 
Tumour details 
Data item Definition Detailed definition 
Histology System used International Classification Diseases -Oncology-3rd edition (ICD-O-3rd edition) (covers the 
entire 2015 World Health Organization (WHO) Classification of Tumours of the Lung) 
Systematized Nomenclature of Medicine (SNOMED) 
 
Based on which system is used, a list of possible options will appear, and the correct 
histology field can be ticked. 
 If no recognised system used then drop down menu appears with a limited list  
 1 Small cell carcinoma 
 2 Non-small cell carcinoma (NSCLC) NOS  
 3 Squamous cell carcinoma 
 4 Adenocarcinoma  
 5 Large cell neuroendocrine carcinoma 
 6 Carcinoid-typical 
 7 Carcinoid-atypical 
 8 Adenocarcinoma in situ 
 9 Spindle/pleiomorphic/giant cell NSCLC 
 10 Other (free text box appears) 
 999 Unknown 
Molecular 
analysis* 
Was this 
performed? 
0=No 
1=Yes 
999=don’t know 
Further questions 
only relevant if 
molecular analysis 
performed. 
EGFR mutation 
 
(ICHOM) 
Numerical value 
Indicate presence of EGFR activating mutation 
0=No 
1=Yes 
2=Failed analysis 
999=don’t know 
 If activating 
mutation found, on 
which exon? 
0=not relevant 
1=exon 18 
2=exon 19 
3=exon 21 
999=don’t know 
 EGFR mutation 
T790M 
Indicate presence of EGFR  mutation of resistance 
0=No 
1=Yes 
2=Failed analysis 
999=don’t know 
 ALK translocation 
 
(ICHOM) 
Numerical value 
Indicate presence of ALK translocation 
0=No 
1=Yes 
2=failed analysis 
999=don’t know 
 Ros 1 Indicate presence of Ros1 translocation 
0=No 
1=Yes 
2=failed analysis 
999=don’t know 
 BRAF Indicate presence of BRAF mutation 
0=No 
1=Yes 
2=failed analysis 
999=don’t know 
 PD-L1 status Indicate PD-L1 status 
0=Not expressed 
1=Some expression 
2=failed analysis 
999=don’t know 
 PD-L1 percent 
expression 
0=not applicable (ie 0 above) 
1=<1 
2=1-9.9% 
3=10-49% 
4=>50% 
 RET Indicate presence of RET translocation 
0=No 
1=Yes 
2=failed analysis 
999=don’t know 
 MET Indicate presence of MET amplification 
0=No 
1=Yes 
2=failed analysis 
999=don’t know 
 MET exon 14 Indicate presence of MET mutation exon 14 
0=No 
1=Yes 
2=failed analysis 
999=don’t know 
 HER 2 Indicate presence of HER2 mutation 
0=No 
1=Yes 
2=failed analysis 
999=don’t know 
* Annual updates expected as molecular medicine develops 
Stage Final pre-treatment clinical stage 
Basis of stage What method was 
used to decide the 
final pre-treatment 
clinical stage? 
 
Numerical value 
0=imaging only 
1=imaging AND non-surgical pathology samples 
2=imaging and surgical biopsies (mediastinoscopy, VATS procedure) 
999=Don’t know 
Definition of non-surgical samples; 
EBUS, EUS, percutaneous lung or pleural biopsy, pleural aspiration, bronchoscopy. 
Investigations 
performed? 
CT scan 
 
Numerical value 
0=No 
1=Yes 
999=Don’t know 
 PET-CT 0=No 
1=Yes 
999=Don’t know 
 Bronchoscopy 0=No 
1=Yes 
999=Don’t know 
 EBUS 0=No 
1=Yes 
999=Don’t know 
 EUS 0=No 
1=Yes 
999=Don’t know 
 Mediastinoscopy 0=No 
1=Yes 
999=Don’t know 
 Histopathology or 
cytology from node 
outside chest 
0=No 
1=Yes 
999=Don’t know 
 Sampling of pleura or 
pleural fluid 
aspiration (medical) 
0=No 
1=Yes 
999=Don’t know 
 VATS thoracoscopy 0=No 
1=Yes 
999=Don’t know 
 Imaging of 
metastasis  
(e.g.; CT/MRI brain, 
MRI spine, MRI 
adrenal etc) 
0=No 
1=Yes 
999=Don’t know 
 Histopathology of 
metastasis 
(eg liver biopsy) 
0=No 
1=Yes 
999=Don’t know 
 Exploratory open 
thoracic surgery 
0=No 
1=Yes 
999=Don’t know 
Tumour size Numerical value The longest single direction size (cm to one decimal point, e.g.3.2) 
Staging system Which staging 
system has been 
used? 
UICC 7th or 8th 
 
Based on this answer; drop down menu appears for T, N and M stage. 
Tumour stage Mixed value UICC Version 7; 1a through to 4 
UICC Version 8; 1mi through to 4 
 
999=Unknown/X 
Nodal stage Mixed value 
 
Version 7 or 8; 0 to 3 
 
999=unknown 
Extent of N1 
disease 
Numerical value 0=Not applicable 
1=Single station N1 disease 
2=Multi-station N1 disease 
Extent of N2 
disease 
Numerical value 0=Not applicable 
1= microscopic N2 node found at final pathological (post-operative) specimen, 
2= Single station N2 node without N1 disease (‘skip’ lesion)  
3= Single station N2 node with N1 involvement 
4= Multi-station N2 disease 
5= Bulky or fixed multi-station N2 disease 
Metastasis stage Mixed value 
 
 
Version 7: 0 through to 1b 
Version 8; 0 through to 1c 
999=unknown/X 
Number of 
metastatic lesions 
Numerical value 0=no metastatic spread (ie M0 above) 
1, 2, 3 onwards 
999=don’t know 
Site of metastases Liver 
 
Numerical value 
0=no 
1=Yes 
If yes, specify number of metastatic lesions 1, 2, 3 onwards 
999=don’t know 
 Brain 0=no 
1=Yes 
If yes, number of metastatic lesions 1, 2, 3 onwards 
999=don’t know 
 Adrenal 0=no 
1=Yes 
If yes, specify number of metastatic lesions 1, 2, 3 onwards 
999=don’t know 
 Bone 0=no 
1=Yes 
If yes, specify number of metastatic lesions 1, 2, 3 onwards 
999=don’t know 
 Other Free text box to confirm site of spread 
 
Extended patient features 
Data item Definition Detailed definition 
Performance status 
(final pre-treatment) 
ECOG (WHO) Numerical value 
0-4 
999=unknown 
 0 Able to carry out all normal activity without restriction 
 1 Restricted in physically strenuous activity, but able to walk and do light work 
 2 Able to walk and capable of all self-care, but unable to carry out any work. Up and about 
more than 50% of waking hours 
 3 Capable of only limited self-care, confined to bed or chair more than 50% of waking hours 
 4 Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair 
 999 Unknown/not recorded 
Smoking status Numerical code 
 
(ICHOM) 
1=never smoker (<100 cigarettes ever) 
2=ex-smoker (stopped at least 1 year before inclusion, ie diagnosis) 
3=current smoker 
999=don’t know 
Smoking pack years Numerical value Simply the number of pack years smoked, regardless of ex or current smoker, 
Eg 20, 40, etc 
999=don’t know 
Comorbidity at 
baseline 
From medical 
consultation with 
patient 
 
ICHOM modified 
Self-administered 
Comorbidity 
Questionnaire 
(SCQ; Sangha et al 
2003) 
 
Drop down menu; 
multiple options 
possible 
Have you been told by a doctor that you have any of the following: 
0=I have no other diseases 
1=Heart disease (eg, angina, heart attack or heart failure) 
2=High blood pressure 
3=Leg pain when walking due to poor circulation 
4=Lung disease (eg, asthma, chronic bronchitis, COPD, or emphysema) 
5=Diabetes 
6=Kidney disease 
7=Liver disease 
8=Problems caused by stroke 
9=Disease of the nervous system (eg, Parkinson disease, multiple sclerosis) 
10=other cancer (within the last 5 years) 
11=Depression 
12=Arthritis 
Weight Numerical value In kg. 
999=don’t know 
Height Numerical value In m 
999=don’t know 
Lung function 
(at baseline) 
Numerical value 
(ICHOM) 
Observed FEV1 (L)  (e.g. 1.35) 
999=don’t know 
 Numerical value 
(ICHOM) 
Percent predicted FEV1   (e.g. 56, would represent 56% predicted) 
999=don’t know 
 Numerical value Observed FVC (L)   (e.g.. 2.3) 
999=don’t know 
 Numerical value 
 
Percent predicted transfer factor (KCO)  (e.g. 85 would represent 85% predicted) 
Numerical value 
999=don’t know 
Quality of Life 
At diagnosis EORTC QLQ-C30 Score (maximum value 126) 
At end of 1
st
 line 
treatment 
EORTC QLQ-C30 Score (maximum value 126) 
At 6 months post 
diagnosis 
EORTC QLQ-C30 Score (maximum value 126) 
 
Lung cancer outcomes 
Data item Definition Detailed definition 
Lung Cancer Nurse 
Specialist (LCNS)  
Contact made 
with LCNS 
0=no 
1=Yes 
999=Don’t know 
Treatment 
Treatment intent 
(reflects the intent of 
the treating physician 
or MDT) 
Numerical code 1=curative intent 
2=non-curative intent 
3=no active treatment 
999=don’t know 
 Curative This is single or multimodality treatment which is hoped will remove the threat of lung 
cancer on the patient’s life expectancy. 
 Non-curative This is single or multimodality treatment which is expected to gain local control, or limit the 
progression of the disease, but unlikely to remove the threat of lung cancer on the patient’s 
life expectancy. 
 No active 
treatment 
This would be those patients who decline, or are too frail for, radiotherapy or chemotherapy 
and simply receive medication for symptom control or a watch and wait policy 
First line treatment given to primary tumour 
 Numerical code Choose one option only from list below. 
 1 Surgery alone 
 2 Hyperfractionated radiotherapy 
 3 External beam radiotherapy (curative intent but not CHART) 
 4 Stereotactic Radiotherapy 
 5 Radiofrequency/microwave ablation 
 6 Brachytherapy 
 7 Palliative radiotherapy to lung primary 
 8 Concurrent chemo-radiotherapy 
 9 Sequential chemo-radiotherapy 
 10 Induction radiotherapy (pre surgery) 
 11 Induction chemotherapy (pre surgery) 
 12 Palliative Chemotherapy 
 13 Targeted/biological therapy (TKI etc) 
 14 Immunotherapy 
 15 Interventional bronchoscopy 
 16 Specialist palliative care 
 17 Other (free text) 
 999 Don’t know/not recorded 
First line treatment not given or change 
in treatment plan 
0=Not relevant 
1=Patient declined 1st line treatment offered 
2=Patient deteriorated and no longer eligible for 1st line treatment 
3=Hospital unable to provide 1st line treatment 
4= other (free text) 
Date of 1st line 
treatment 
dd/mm/yyyy Date of the start of 1st line treatment, ie date of operation, or first day of radiotherapy or 
chemotherapy regime, or appointment with specialist palliative care physician. 
Type of operation 
Additional question 
only if option 1 above 
Numerical value 0=incomplete resection (residual macroscopic disease evident) 
1=segmentectomy 
2=wedge resection 
3=lobectomy 
4=bi-lobectomy 
5=sleeve lobectomy 
6=pneumonectomy 
999=don’t know 
Pathological stage 
Additional question 
only if option 1 above 
Staging system 
used 
IASLC version 7 or 8 
 Pathological Based on version used can then have drop down menu for pathological stage  
stage 
Nature of 
radiotherapy 
Additional questions 
only if options 2,3,4,7 
or 10 chosen 
Total dose given 
(Grey) 
 
Absolute number. 
 Number of 
fractions 
Absolute number (eg 6) 
 Number of days 
or radiotherapy 
treatment 
Absolute number (eg. 12) 
Nature of 
chemotherapy 
Additional question 
only if options 11 or 
12 chosen 
Numerical value 1=single agent chemotherapy 
2= Doublet platinum-based chemotherapy 
3=other (free text) 
999=don’t know 
Additional supportive 1st line treatment given? 
 Numerical value 0=No 
1=Yes 
If yes then further question appears 
Type of additional supportive 1
st
 line treatment  
 Numerical value  
 1 Stereotactic radiotherapy to brain metastases 
 2 Radiotherapy for spinal cord compression 
 3 Prophylactic Cranial Irradiation 
 4 Whole brain radiotherapy 
 5 Radiotherapy for oligometastases 
 6 SABR for oligometastases 
 7 Radiotherapy for SVCO 
 8 Radiotherapy to mediastinum 
 9 Specialist palliative care 
 10 Surgical resection of metastases 
 11 Pleural intervention (see below) 
 12 Other (free text) 
Date of first 
radiotherapy session 
dd/mm/yyyy  
Nature of 
radiotherapy (1-8) 
Total dose given 
(Grey) 
Absolute number (e.g. 30) 
 Number of 
fractions 
Absolute number (e.g. 6) 
 Number of days 
or radiotherapy 
treatment 
Absolute number (e.g. 12) 
Date of palliative care dd/mm/yyyy Date of first appointment with specialist palliative care physician 
Date of surgery dd/mm/yyyy  
Date of pleural 
intervention 
dd/mm/yyyy  
Type of Pleural 
intervention 
Numerical value 1=thoracocentesis 
2=chest drain 
3=pleurodesis 
4=indwelling chest drain 
How is the patient 
followed up after 1st 
line treatment? 
Numerical 
value, please 
pick single item 
from list. 
Options are 
ranked in 
descending 
order. If 
multiple 
answers apply, 
please pick the 
first answer in 
the list 
1=Regular out-patient visits with physician (member of MDT) 
2=Follow up with lung cancer nurse specialist 
3=Virtual follow-up after imaging 
4=Phone contact with patient 
5=Referred back to primary care doctor 
0=No follow-up 
999=don’t know 
Date of completion of 
1st line treatment 
dd/mm/yyyy  
Response to 1st line 
treatment? 
Numerical value 0=Complete remission 
1=Partial response 
2=Stable disease 
3=Progression 
999=don’t know 
Date of relapse dd/mm/yyyy  
How was relapse 
detected? 
 0=Planned imaging 
1=Symptoms 
2=Incidental finding with unrelated problem 
999=don’t know 
Subsequent treatment to lung primary 
 Numerical code More than one treatment option can be chosen during the patient treatment programme 
(please confirm with dates below) 
 1 Surgery 
 2 Chemotherapy and radiotherapy in addition to surgery (tri-modality treatment) 
 3 Hyperfractionated radiotherapy 
 4 External beam radiotherapy (curative intent but not CHART) 
 5 Stereotactic Radiotherapy (3-8 fractions) 
 6 Radiofrequency/microwave ablation 
 7 Brachytherapy 
 8 Palliative radiotherapy to lung primary 
 9 Concurrent chemo-radiotherapy 
 10 Sequential chemo-radiotherapy 
 11 Palliative Chemotherapy 
 12 Targeted/biological therapy (TKI etc) 
 13 Immunotherapy 
 14 Interventional bronchoscopy 
 15 Specialist palliative care 
 999 Don’t know/not recorded 
Date of surgery dd/mm/yyyy  
Date of first 
radiotherapy session 
dd/mm/yyyy  
Nature of 
radiotherapy 
Total dose given 
(Grey) 
Absolute number (e.g. 30) 
 Number of 
fractions given 
Absolute number (e.g. 6) 
 Number of days 
or radiotherapy 
treatment 
Absolute number (e.g. 12) 
Date first 
chemotherapy started 
dd/mm/yyyy  
Date of last 
chemotherapy dose 
dd/mm/yyyy  
Date of interventional 
bronchoscopy 
dd/mm/yyyy  
Date of specialist 
palliative care 
dd/mm/yyyy Date of first appointment with specialist palliative care physician 
Clinical trial Is the patient 
part of a clinical 
trial? 
0=No 
1=Yes 
 
999=Don’t know 
Date of death dd/mm/yyyy  
Legend: data items in black are mandatory within the proposed minimum dataset; those in blue are desirable 
dataset. 
Dd/mm/yyyy; Date, month and year.  
  
Supplement 2 
 
 
Manual of parameters for a lung cancer service in Europe- organisation 
 
I. Organization of Lung Cancer Service 
1. General Structure of Lung Cancer Service and adjacent Network 
2. Multidisciplinary Team Structure 
3. Patient- and Carer-centred Care 
4. Evidence-based Lung Cancer Care Programme 
5. Access to Care and Timeliness of Care 
6. Documentation, Accessibility and Provision of Patient- and Care-related Information 
7. Schedule of Meetings 
8. Education for Healthcare Professionals, Patients and Carers 
9. Clinical Cancer Registry 
10. Collaboration with External Healthcare Professionals and other External Stakeholders 
11. Quality Assurance and Quality Improvement, Risk Management 
 
I. Organization of Lung Cancer Service Derived from 
1. General Structure of Lung Cancer Service and adjacent Network  
Essential: The general structure of the lung cancer service must include a multi-
disciplinary team composed of the disciplines and professions listed in detail in  I.2.  
However, the underlying organizational form may vary according to the respective 
national health care system as well as the regional and local needs.  
In principle, various structural solutions are conceivable to achieve the demanded 
comprehensive multidisciplinary structure. These could include but not limited to (see 
figure 1): 
 all-on-one-site-solutions run by one provider 
 multiple-site-solutions run by one or more providers 
 one centralized site (i.e. PET CT, thoracic surgery service) and multiple satellite sites 
 clinical network solutions with all health care components addressing lung cancer 
care in a geographical region driven by a national health care system  
 
The lung cancer service must describe its internal structure as well as potential 
involvement of its adjacent network.  
 
Besides, the Lung cancer service should provide some basic epidemiological facts about 
itself (i.e. number of new lung cancer cases per year and the size of the general 
population covered by the service). 
 
Good practice 
Advanced: According to regional or local needs, the lung cancer service should provide 
their expertise in lung cancer care to other neighbouring services who cannot fulfil all 
criteria of this catalogue. Provision of expertise could include among other things: 
 Second opinion-services 
 Referral of patients from other services to the lung cancer service for certain 
diagnostics or treatment  
 Deployment of qualified personnel from the lung cancer service to other services 
 Teaching site for training of personnel of other services 
 Offering inclusion in clinical trials (regularly phase III optional early stage phase II or 
I) 
Good practice 
2. Multidisciplinary Team Structure  
Essential: The following disciplines and professions must be included the Good practice 
multidisciplinary team of the lung cancer service or available to in reasonable time: 
 Pulmonology 
 Radiology 
 Nuclear medicine 
 Pathology/Molecular biology 
 Thoracic Surgery 
 Medical Oncology/Pneumo-oncology 
 Radiotherapy 
 Palliative care medicine 
 Emergency medicine/Intensive care medicine 
 Lung cancer specialised Nurse 
 Physiotherapy service 
 Psychology service 
 Social work service 
 Data collection management/clinical lung cancer registry 
 
It is acknowledged that in certain national or regional health care settings specific 
disciplines or professions are not designated and/or their service portfolio is integrated 
in other disciplines or professions. In these particular cases, the lung cancer service 
should describe the equivalent alternative solution. 
Advanced: The following disciplines and professions should be included in the 
multidisciplinary team of the lung cancer service or should be available for access: 
 Nutrition counselling service 
 Pain management service 
 Hospice 
 Patient pathway coordination  
 Clinical research management (including study nurses) 
 Quality management for continuous evaluation and improvement of lung cancer 
service quality 
 
Depending on respective cultural habits, a separate Spiritual service could also be 
included in the multidisciplinary team of the lung cancer service.  
 
Good practice 
3. Patient- and Carer-centred Care  
Essential: The lung cancer service must give patient- and carer-centred care high 
priority and therefore install the following measures (if not already installed within 
superordinate institutional setting): 
 Implementing and regular training of a good communication between 
patients/carers and healthcare professionals within the lung cancer service which 
focusses on: 
o Breaking bad news and informing patients and their carers on MDT 
discussions and recommendations (including incorporation of patient 
preferences) 
o Shared decision-making 
 Structured approach in the lung cancer service to discuss and support patients in 
advance decision making and formulation of patient advance care directive 
 Incorporation of patient input 
 Provision of information about the lung cancer services (i.e. access and contact 
data, recognition of and proper reaction to potential side effects of treatment) with 
input from patients and/or reviewed by patients which are issued through various 
communication channels (i.e. leaflets, website) for patients and their carers  
 Installation of a patient advocate/ombudsman 
 Installation of a complaint management system for patients and their carers ( 
I.11) 
 Cooperation with local, regional and/or national patient organization if applicable 
Good practice 
 Organization of at least one annual patient event 
  
Advanced: The lung cancer service should install the following patient- and carer-
centres measures (if not already installed within superordinate institutional setting):  
 Provision of translators for patients unable to speak native language of respective 
country of lung cancer service 
 Performance of patient satisfaction surveys with subsequent evaluation and if 
needed adaption of own processes ( I.11) 
 Installation of a patient advocate/ombudsman 
 Installation of a complaint management system for patients and their carers ( 
I.11) 
 Organization of an education programme for patients and their carers ( I.8) 
 Consultation with patients on the design and development of new services within 
the lung cancer service 
 
Good practice 
4. Evidence-based Lung Cancer Care Programme  
Essential: The lung cancer service must build its own practices of care on valid scientific 
evidence, namely medical guidelines or other scientific evidence that is accepted by the 
international medical community* with the view to offer a personalised management 
plan to each patient. Accordingly, the lung cancer service must define one 
comprehensive guideline or separate guidelines as the valid scientific, internally 
consented basis for the following relevant parts within its covered lung cancer 
continuum: 
 Diagnostics: 
o Initial Assessment 
o Functional Assessment, Appraisal of Fitness for Diagnostics and Therapy 
o Imaging 
o Endoscopy 
o Percutaneous Image-guided Biopsy Procedures 
o Mediastinoscopy 
o Medical Thoracoscopy, Video-assisted Thoracoscopy (VATS) 
o Tissue-based Tumour Sampling 
o Biofluid-based Tumour Sampling 
o Pathology and Molecular Diagnostics 
o TNM Description and Stage Grouping 
 Medical Decision-finding and Care Planning with Patients and within the 
Multidisciplinary Team 
 Tumour-specific Therapy 
o Thoracic Surgery 
o Systemic Therapy 
o Radiotherapy 
o Multimodal Therapy 
 Re-Staging and Follow-up during and after Therapy 
 Management of Progressive Disease and Relapse 
 End-of-life Care, Death and Bereavement Period 
 Survivorship 
 Cross-pathway Care 
o Tumour- and Care-related Side Effect Management 
o Emergency Care 
o Palliative Care 
o Specialised Nursing 
o Physiotherapy and Rehabilitation 
o Social Work Service 
o Psychology 
o Nutrition Counselling 
o Pain Management 
Good practice 
o Smoking Cessation 
 
The lung cancer service must check at least annually its underlying evidence basis for 
own practices of care on currentness and update as needed. An annual operational 
meeting of all multidisciplinary team members should be held for these updates to 
ensure that all services of the clinical network follow similar processes and meet quality 
standards. 
According to national, regional and local conditions, the lung cancer service must 
provide written standard operating procedures adapted from the above-mentioned 
underlying evidence to its individual needs and circumstances. Likewise, the lung cancer 
service must check at least annually its local standard operating procedures on 
currentness and update as needed. 
 
*If qualified guidelines on specific topics are unavailable or out-of-date, the lung cancer service should refer to 
up-to-date, peer-reviewed systemic reviews/meta-analysis as second best or single publications as third best 
source of evidence. 
5. Access to Care and Timeliness of Care  
Essential: Depending on its own capacities, the lung cancer service must ensure equal 
and rapid access to its care independent from gender, ethnicity and socio-economic 
status of patients. 
 
The lung cancer service should ensure reasonable internal timeliness and avoid waiting 
time whenever possible.  
 
However, at present, specific maximum waiting times with prognostic relevance cannot 
be justified. 
 
Good practice 
 
 
 
 
 
 
Literature review 
and assessment  
Advanced: For the purpose of improvement of quality of care, the lung cancer service 
should measure and evaluate the following time intervals within its internal lung cancer 
pathway in its patients at least on a sample basis: 
 Time interval from date of admission to lung cancer services to date of first 
diagnosis 
 Time interval from date of diagnosis-confirming specimen collection to date of final 
pathology/molecular diagnostics report creation 
 Time interval from date of first diagnosis to date of MDT conference treatment 
recommendation 
 Time interval from date of first diagnosis to date of first treatment start 
 
Good practice 
6. Documentation, Accessibility and Provision of Patient- and Care-related 
Information 
 
Essential: The lung cancer service must provide an internal documentation and 
information system which is accessible to all of its healthcare professional and which 
provides all relevant patient- and care-related information, in compliance with national 
legal regulations. 
 
Good practice 
7. Schedule of Meetings  
Essential: The lung cancer service must provide a schedule of meetings which includes 
all relevant modes of communication as well as meetings within the lung cancer service 
as well as between the lung cancer service and external healthcare professionals, 
patients and their carers and other external stakeholders 
 
Good practice 
8. Education for Healthcare Professionals, Patients and Carers  
Essential: The lung cancer service should install a comprehensive educational and 
training programme as part of a professional development strategy. 
 
Beside national standards, the lung cancer service should also use the Thoracic 
Oncology HERMES syllabus and curriculum as basis for its own local training 
Good practice 
programme. 
 
Whenever possible, joint educational formats of multiple professions should be sought. 
 
Advanced:  
 
The lung cancer service could act as a training centre for other lung cancer specialists. 
 
The lung cancer service should offer a regular journal club for professionals. 
 
Preferably, the lung cancer service should be linked to a library or to electronic library 
services. 
 
The lung cancer service should install an educational programme for its patients and 
their carers. 
 
Good practice 
9. Clinical Cancer Registry  
Essential: The lung cancer service must install a clinical cancer registry for 
documentation of its own lung cancer patients as well as quality of case ascertainment. 
 
Good practice 
Advanced: If a national clinical lung cancer registry is already available, the lung cancer 
service should contribute its data derived from its own clinical cancer registry or use the 
national clinical cancer registry platform for its own needs according to applicable data 
security regulations. 
 
Beside national standards, the lung cancer service should also integrate the formulated 
standards for lung cancer registration within this ERS statement paper as basis of its 
own clinical lung cancer registry. However, duplication of registries should be avoided. 
 
Good practice 
10. Collaboration with External Healthcare Professionals and other External 
Stakeholders 
 
Essential: The lung cancer service must identify and list its collaborating external 
healthcare professionals (if applicable)  and other external stakeholders as well as 
describe the existing interfaces between the lung cancer service and the external 
healthcare professionals/other external stakeholders. 
 
A good link to cooperating general practitioners should be sought in order to allow quick 
and complete transmission of patient information (i.e. MDT conference decision, 
treatment schedule) 
Good practice 
Advanced: The lung cancer service should aim to further develop its collaborations with 
external healthcare professionals via the following or similar measures: 
 At least annual network meetings with external healthcare professionals 
 Joint quality improvement initiatives with external healthcare professionals or 
other external stakeholders 
 Contribution of own clinical lung cancer registry data to regional, national and 
international epidemiological and/or clinical cancer registries, based on national 
legal regulations 
 
Good practice 
11. Quality Assurance and Quality Improvement, Risk Management  
Essential: If no superordinate quality assurance/improvement systems are available, the 
lung cancer service must install a basic quality assurance and quality improvement 
system in order to assure regular evaluation and if needed optimization of processes. 
Good practice 
Essential: The lung cancer service must perform at least annual satisfaction surveys 
among patients, external healthcare professionals and own staff members. 
 
Timeliness of care should be regularly evaluated in order to adapt and optimize internal 
Good practice 
 
 
 
processes. 
 
A core set of quality performance indicators should be assessed, i.e. recording of stage, 
surgical resection rates, overall survival 
 
 
 
Literature review 
and assessment  
Advanced: The lung cancer service should use one or more of the following measures 
for internal quality assurance and quality improvement as well as risk management: 
 Internal audits of the lung cancer pathway 
 Peer reviews 
 Regular internal morbidity and mortality conferences 
 Complaint management system for patients and their carers as well as external 
healthcare professionals 
 Risk management system 
 Regular evaluation of the own clinical lung cancer registry, including the set-up and 
usage of a comprehensive quality performance indicator system 
Participation in external quality assurance/improvement programmes or external 
certification programmes including visits by external auditors or external lung cancer 
specialists 
The lung cancer service should publish an annual report providing core information on 
its performance and development as well its future plans. 
Good practice 
Manual of parameters for a lung cancer service in Europe- care pathway 
 
II. Lung Cancer Care Pathway 
1. Diagnostics 
i. Core Diagnostic Strategies 
ii. Initial Assessment 
iii. Functional Assessment, Appraisal of Fitness for Diagnostics and Therapy 
iv. Imaging 
v. Endoscopy 
vi. Percutaneous Image-guided Biopsy Procedures 
vii. Mediastinoscopy 
viii. Medical Thoracoscopy, Video-assisted Thoracoscopy (VATS) 
ix. Tissue-based Tumour Sampling 
x. Biofluid-based Tumour Sampling 
xi. Pathology and Molecular Diagnostics 
xii. TNM Description and Stage Grouping 
2. Medical Decision-finding and Care Planning with Patients and within the Multidisciplinary 
Team 
3. Tumour-specific Therapy 
i. Core Strategies for Tumour-specific Therapy  
ii. Thoracic Surgery 
iii. Systemic Therapy 
iv. Radiotherapy 
v. Multimodal Therapy 
4. Re-Staging and Follow-up during and after Therapy 
5. Management of Progressive Disease and Relapse 
6. End-of-life Care, Death and Bereavement Period 
7. Survivorship 
8. Cross-pathway Care 
i. Tumour- and Care-related Side Effect Management 
ii. Emergency Care, Intensive Care 
iii. Palliative Care 
iv. Specialised Nursing 
v. Physiotherapy and Rehabilitation 
vi. Social Work Service 
vii. Psychology Service 
viii. Spiritual Care Service 
ix. Nutrition Counselling 
x. Pain Management 
xi. Smoking Cessation 
xii. Clinical Research  
 
II. Lung Cancer Care Pathway Derived from 
1. Diagnostics  
i. Core diagnostic strategies  
Essential: The lung cancer service must provide written standard operating 
procedures which describe its diagnostic strategies covering: 
 How to generally discuss and decide with patients on their diagnostic strategies 
based on best evidence-based practices and their status as well as their needs 
and desires 
 How to perform the initial assessment of patients 
 How to perform functional assessment and appraisal of fitness for diagnostics 
and therapy in patients with curative and palliative therapy intent 
 How to decide in which patients to seek pathological confirmation of suspected 
lung cancer and in which to avoid it 
Good practice 
 How to seek pathological confirmation in suitable patients with suspected lung 
cancer, addressing both obtaining adequate tumour material and performing 
adequate pathological and molecular analyses 
 How to search for presence of and – if suspected or proven – how to stage 
extent of primary tumour, logo-regional lymph node metastases and distant 
metastases, respectively, as well as how to derive stage grouping out of the 
findings 
Multidisciplinary team play in the diagnostic phase involves in particular 
pulmonology, thoracic surgery, radiology, nuclear medicine and 
pathology/molecular diagnostics – interdisciplinary interfaces must be described in 
written form within the named standard operating procedures. 
Advanced: Without slowing down processes, the lung cancer service should provide 
a rapid initial multidisciplinary appraisal of the imaging material and other findings 
by pulmonologist, thoracic surgeon and radiologist for uncertain or complicated 
cases to jointly specify the best diagnostic procedure for tumour sample collection in 
suitable patients. This recommendation should be based on patient-specific risk-
benefit analyses for the eligible procedures and patient preferences. 
Good practice 
ii. Initial assessment  
Essential: The lung cancer service must ensure that in every patient as initial 
assessment a comprehensive patient history*, a multidimensional symptom 
assessment**, a complete physical examination*** and a blood analysis*** is 
performed and based on these findings a first fitness assessment for diagnostic and 
therapeutic procedures is made. 
 
*including occupational history, comorbidities, and socio-economic status 
**dimensions to be covered: physical, psychological, social and spiritual; Performance status and 
weight/height to be assessed 
***including a focus on potential signs for paraneoplastic syndromes [i.e. sodium, calcium] and systemic 
inflammation [i.e. CRP and/or albumin] 
Guideline 
Functional Assessment, Appraisal of Fitness for Diagnostics and Therapy 
Essential: The lung cancer service must provide or have access to the following tests 
for functional assessment and appraisal of fitness for diagnostics and therapy (not all 
will apply in every patient): 
 Blood gas analysis 
 Spirometry 
 Body plethysmography 
 Diffusing capacity for carbon monoxide (via breath holding or single breath 
method) 
 Electrocardiogram 
 Spiroergometry 
 Echocardiography 
 
Guideline 
Staff requirements: All functional assessment tests should be performed by 
specifically qualified and trained personnel (ordinarily, pulmonologists and 
respective medical assistance personnel; echocardiography: cardiologists). 
 
Staff quantity should be sufficient. However, at present, a specific minimum number 
of staff cannot be justified. 
 
Good practice 
Volume of care: At present, a specific minimum individual or institutional volume 
threshold for number of imaging tests with prognostic relevance cannot be justified. 
 
Literature review and 
assessment 
Time standards: All functional assessment tests should be available in reasonable 
time.  
 
However, at present, a specific maximum time with prognostic relevance for 
performance of functional assessment test cannot be justified. 
Good practice 
 
 
Literature review and 
assessment 
iii. Imaging  
Essential: The lung cancer service must provide or have access to the following tests 
for imaging: 
 Conventional x-ray 
 Computed tomography (CT) 
 Magnetic resonance imaging 
 Lung perfusion and ventilation scintigraphy 
 Bone scintigraphy 
 Positron emission tomography/Computed tomography (PET/CT) 
 Ultrasound  
 Fluoroscopy [also needed for endoscopy  II.1.v.] 
 
The lung cancer service should provide a direct link between imaging and image-
guided biopsies  II.1.vi 
Guideline 
Staff requirements: All imaging tests should be performed by specifically qualified 
and trained personnel (ordinarily, radiologists and/or nuclear medicine specialists 
and respective medical assistance personnel; ultrasound, fluoroscopy: multiple 
qualified disciplines).  
 
Staff quantity should be sufficient. However, at present, a specific minimum number 
of staff cannot be justified. 
 
Good practice 
Volume of care: At present, a specific minimum individual or institutional volume 
threshold for number of imaging tests with prognostic relevance cannot be justified. 
 
Literature review and 
assessment 
Time standards: All imaging tests should be available daily in emergencies or urgent 
cases, otherwise in reasonable time.  
 
However, at present, a specific maximum time with prognostic relevance for 
performance of non-emergency imaging tests cannot be justified. 
Good practice 
 
 
Literature review and 
assessment 
iv. Endoscopy  
Essential: The lung cancer service must provide or have access to the following 
endoscopy procedures: 
 Flexible and rigid bronchoscopy with: 
o Forceps biopsies for central bronchial lesions or peripheral pulmonary 
lesions (under fluoroscopy) 
o Transbronchial needle biopsies for central bronchial lesions or 
peripheral pulmonary lesions (under fluoroscopy or EBUS mini probe) 
o Brushing and washing 
o Bronchoalveolar lavage (BAL) 
 Endobronchial ultrasound (EBUS) 
 Endoscopic ultrasound (EUS) 
 
Further, the lung cancer service must provide or have access to the following 
interventional endoscopic procedures (may already become relevant in diagnostic 
period; therapeutic period:  II.8.i.): 
 Recanalisation with one or more of the following procedures:  
o Laser 
o Electrocoagulation 
o Cryotherapy 
 Stenting 
 
Guideline 
Staff requirements: All endoscopic procedures should be performed by specifically 
qualified and trained personnel (ordinarily, pulmonologists or thoracic surgeons and 
respective medical assistance personnel).  
 
Good practice 
Staff quantity should be sufficient. However, at present, a specific minimum number 
of staff cannot be justified. 
 
Volume of care: At present, a specific minimum individual or institutional volume 
threshold for number of endoscopic procedures with prognostic relevance cannot 
be justified. 
 
Literature review and 
assessment 
Time standards: All endoscopic procedures should be available daily in emergencies 
or urgent cases, otherwise within reasonable time.  
 
However, at present, a specific maximum time with prognostic relevance for 
performance of non-emergency endoscopic tests cannot be justified. 
Good practice 
 
 
Literature review and 
assessment 
Advanced: The lung cancer service should provide or have access to one or more of 
the following endoscopic procedures: 
 Flexible and rigid bronchoscopy with: 
o Central cryobiopsy probe 
o Peripheral transbronchial cryobiopsy probe (under fluoroscopy) 
o Peripheral endobrochial ultrasound (EBUS) mini probe (under 
fluoroscopy) 
o Navigational techniques 
Good practice 
 
v. Percutaneous Image-guided Biopsy Procedures  
Essential: The lung cancer service must provide or have access to either one or both 
of the following percutaneous image-guided biopsy procedures: 
 Ultrasound-guided biopsy 
 Computed tomography-guided biopsy 
 
among other things for: 
 Pleurocentesis 
 Pericardiocentesis/pericardial drainage 
 Peritoneocentesis 
 Biopsy of pleural lesions 
 Biopsy of pulmonary lesions 
 Lymph node biopsy 
 Liver biopsy 
 Bone biopsy 
 Renal biopsy 
 Biopsy of cutaneous and subcutaneous lesions 
 
Guideline 
Staff requirements: All percutaneous image-guided biopsy procedures should be 
performed by specifically qualified and trained personnel (ordinarily, interventional 
radiologists, pulmonologists or thoracic surgeons as well as organ-specific disciplines 
and respective medical assistance personnel).  
 
Staff quantity should be sufficient. However, at present, a specific minimum number 
of staff cannot be justified. 
 
Good practice 
Volume of care: At present, a specific minimum individual or institutional volume 
threshold for number of percutaneous image-guided biopsy procedures with 
prognostic relevance cannot be justified 
 
Literature review and 
assessment 
Time standards: All percutaneous image-guided biopsy procedures should be 
available in reasonable time.  
 
However, at present, a specific maximum time with prognostic relevance for 
performance of percutaneous image-guided biopsy procedures cannot be justified. 
Good practice 
 
 
Literature review and 
assessment 
vi. Mediastinoscopy  
Essential: The lung cancer service must provide or have access to mediastinoscopy 
as a diagnostic procedure. 
Guideline 
Staff requirements: Mediastinoscopy should be performed by specifically qualified 
and trained personnel (ordinarily, thoracic surgeons and respective medical 
assistance personnel).  
 
Staff quantity should be sufficient. However, at present, a specific minimum number 
of staff cannot be justified. 
 
Good practice 
Volume of care: At present, a specific minimum individual or institutional volume 
threshold for number of mediastinoscopies with prognostic relevance cannot be 
justified. 
 
Literature review and 
assessment 
Time standards: Mediastinoscopy should be available in reasonable time.  
However, at present, a specific maximum time with prognostic relevance for 
performance of mediastinoscopy cannot be justified. 
Good practice 
 
Literature review and 
assessment 
vii. Medical Thoracoscopy, Video-assisted Thoracoscopy (VATS)  
Essential: The lung cancer service must provide or have access to video-assisted 
thoracoscopy as a diagnostic and therapeutic [ II.8.i] procedure. 
 
Guideline 
Essential: If the lung cancer service provides additionally medical thoracoscopy as a 
diagnostic and therapeutic [ II.8.i] procedure, patient selection criteria for each of 
the two procedures should be consented in written form by the pulmonology and 
the thoracic surgery department. 
 
Good practice 
 
Staff requirements: Medical thoracoscopy and video-assisted thoracoscopy (VATS) 
should be performed by specifically qualified and trained personnel (ordinarily, 
thoracic surgeons or pulmonologists and respective medical assistance personnel).  
 
Staff quantity should be sufficient. However, at present, a specific minimum number 
of staff cannot be justified. 
 
Good practice 
Volume of care: At present, a specific minimum individual or institutional volume 
threshold for number of medical thoracoscopies or video-assisted thoracoscopies 
(VATS) with prognostic relevance cannot be justified. 
 
Literature review and 
assessment 
Time standards: Medical thoracoscopy and video-assisted thoracoscopy (VATS) 
should be available daily in emergencies or urgent cases, otherwise within 
reasonable time.  
 
However, at present, a specific maximum time with prognostic relevance for 
performance of medical thoracoscopy and video-assisted thoracoscopy (VATS) 
cannot be justified. 
Good practice 
 
 
 
Literature review and 
assessment 
viii. Tissue-based Tumour Sampling  
Essential: Tissue-based tumour sampling can be performed by various methods. The 
lung cancer service must provide written standard operating procedures addressing 
in particular performance of and post-interventional sample handling in the 
following procedures: 
 bronchoscopic forceps probes, central and peripheral 
 bronchoscopic needle probes, central and peripheral 
 bronchoscopic cryobiopsy probes, central and peripheral (if applied) 
 EBUS probes, central and peripheral 
 EUS probes 
 Percutaneous ultrasound-guided probes 
 Percutaneous computed tomography-guided probes 
Guideline 
 Mediastinoscopic probes 
 Medical thoracoscopic probes (if applied) 
 Video-assisted thoracoscopic (VATS) probes 
 
ix. Biofluid-based Tumour Sampling  
Essential: Biofluid-based tumour sampling can be performed by various methods. 
The lung cancer service must provide written standard operating procedures 
addressing in particular performance of and post-interventional sample handling in 
the following procedures: 
 Blood sample 
 Bronchoalveolar lavage (BAL) 
 Brushing and washing 
 Sputum sample 
 Pleurocentesis 
 Pericardiocentesis 
 Peritoneocentesis 
 Spinal tap 
 
Guideline 
Advanced: The lung cancer service should provide the option to use blood or urine 
to obtain tumour samples for molecular diagnostics. Accordingly, the lung cancer 
service should provide written standard operating procedures addressing in 
particular performance of these specific biofluid-based tumour sampling methods 
and their post-interventional sample handling. 
 
Guideline 
x. Pathology and Molecular Diagnostics  
Essential: The lung cancer service must provide or have access to the following 
methods for pathology and molecular diagnostics: 
 Light microscopy 
 Immunohistochemistry 
 First generation sequencing (i. e. Sanger polymerase chain reaction [PCR]) 
 Fluorescence in situ hybridization (FISH) (depending on molecular testing 
strategies) 
 
Written standard operating procedures must be provided by the lung cancer service 
for each of these methods as well as the general diagnostic strategy with regard to 
pathology and molecular diagnostics. 
 
Guideline 
Advanced: The lung cancer service should provide the following method for 
molecular diagnostics:  
 Next generation sequencing (NGS) 
 
Good practice 
Essential: The lung cancer service must apply the 2015 World Health Organization 
Classification of Lung Tumours for pathological subtyping of lung cancer. 
 
Guideline 
Essential: The lung cancer service must be capable to detect the following routinely 
treatable molecular alterations within its molecular diagnostics or have access to an 
appropriate external cooperation partner: 
 EGFR mutations 
 EML-4-ALK rearrangements (alternatively, immunohistochemistry can be used 
as equivalent alternative to FISH) 
 ROS1 rearrangements 
as well as the common alteration (if needed in sequential testing for molecular 
alterations): 
 KRAS mutations 
 
Guideline 
Besides, the lung cancer service must be capable to detect the following treatment-
relevant marker: 
 PD-L1 
 
Advanced The lung cancer service should be capable to detect the following 
routinely treatable molecular alterations within its molecular diagnostics or have 
access to an appropriate external cooperation partner: 
 RET rearrangements 
 MET exon 14 splice mutations 
 C-MET amplification 
 HER2 alterations 
 
Guideline 
Essential: The pathology report of the lung cancer service must include the following 
core information: 
a) small biopsy: 
 Macroscopic findings (quantity, localisation and diameter (in mm) of lesions) 
 Microscopic findings 
 Pathological subtyping according to the 2015 World Health Organization 
Classification of Lung Tumors 
 ICD-O-3 code 
 Immunohistochemical findings (according to 2015 World Health Organization 
Classification of Lung Tumors) 
 Molecular diagnostics findings (as listed above) 
 
a) Surgical resection specimen: 
 Macroscopic findings (quantity, localisation and diameter (in mm) of lesions; 
infiltration of adjacent structures; infiltration of surgical margins) 
 Microscopic findings 
 Pathological subtyping according to the 2015 World Health Organization 
Classification of Lung Tumors 
 ICD-O-3 code  
 Immunohistochemical findings (according to 2015 World Health Organization 
Classification of Lung Tumors) 
 Molecular diagnostics (as listed above) 
 Intrapulmonary, hilar and mediastinal lymph nodes with lymph node stations 
(quantity of positive lymph nodes, quantity of dissected lymph nodes) 
 Residual tumour classification 
 TNM-classification and stage grouping according to UICC 8 
 
Guideline 
Essential: The lung cancer service should be able to perform autopsies. 
 
Good practice 
Staff requirements: Pathology and molecular diagnostics should be performed by 
specifically qualified and trained personnel (ordinarily, pathologists and/or 
molecular biologists and respective medical assistance personnel).  
 
Staff quantity should be sufficient. However, at present, a specific minimum number 
of staff cannot be justified. 
 
Good practice 
Institutional requirements: Pathology and molecular diagnostics in the lung cancer 
service should participate in ring trials or other external accreditation measures for 
target-specific test-approvals. 
 
Guideline 
Volume of care: At present, a specific minimum individual or institutional volume 
threshold for number of pathological and molecular diagnostics with prognostic 
relevance cannot be justified. 
Literature review and 
assessment 
 
Time standards: Final results of pathology and molecular diagnostics should be 
available in reasonable time.  
 
However, at present, a specific maximum time with prognostic relevance for 
performance of pathology and molecular diagnostics cannot be justified. 
Good practice  
 
 
Literature review and 
assessment 
xi. TNM Description and Stage Grouping  
Essential: The lung cancer service must apply the UICC 8 version for TNM 
Description and Stage Grouping in lung cancer. 
 
Guideline 
2. Medical Decision-finding and Care Planning with Patients and within the 
Multidisciplinary Team 
 
Essential: The lung cancer service must define its modes of medical decision-finding 
and care planning throughout the entire lung cancer pathway in a written standard 
operating procedure. This standard operating procedure must take into account the 
related communication within the multidisciplinary team as well as between 
members of the multidisciplinary team and patients/carers. 
Guideline 
Essential: One core element of the medical decision-finding and care planning within 
the multidisciplinary team is the multidisciplinary team conference in which patient 
cases are presented and discussed among a multidisciplinary panel as well as 
recommendations with regard to diagnostic and therapeutic questions are 
consented.  
 
The lung cancer service must install and run a multidisciplinary team conference at 
least on a weekly basis. The multidisciplinary conference should be directed by a 
coordinator. 
 
The following disciplines must be present at each multidisciplinary team conference 
either in person or virtually via a web-conference tool (or equal measure): 
 Pulmonology 
 Radiology 
 Nuclear medicine 
 Pathology, Molecular biology 
 Thoracic Surgery  
 Medical Oncology/Pneumo-oncology 
 Radiotherapy 
 
Other disciplines or professions (i.e. palliative care medicine, lung cancer specialised 
nurse) may participate in the multidisciplinary team conference at any time or may 
be invited to join this meeting in selected cases. 
 
The following medical indications in patients with proven or suspected lung cancer 
lead to a case presentation in multidisciplinary team conference: 
 All patients with a first diagnosis of lung cancer 
 All lung cancer patients after surgical lung resection with curative intent with 
regard to adjuvant therapy 
 All lung cancer patients with a newly diagnosed relapse of their disease after 
treatment with curative intent 
 Selected patients with proven or suspected lung cancer with problems or 
specific multiprofessional questions during diagnostics or tumour-specific 
treatment 
 
Every case in the multidisciplinary team conference should be presented to the 
multidisciplinary panel by the doctor who knows the patient and his previous course 
of disease best. To provide all relevant information to everybody in the 
multidisciplinary panel for proper preparation, a registration system is mandatory in 
Good practice 
the lung cancer service. 
 
Every discussed MDT conference-case will be protocolled in written form. The 
written protocol must be made available to patients and their general practitioners 
or other referring physicians  if requested and  if also approved by the patient. 
 
Advanced: The lung cancer service should implement and run a tool for regular 
quality assessment of the multidisciplinary team conference (i.e. concordance rates 
of MDT conference recommendations and actual applied treatments as well reasons 
for deviation) and subsequent quality improvement. 
Good practice 
3. Tumour-specific Therapy  
i. Core Strategies for Tumour-specific Therapy  
Essential: The lung cancer service must provide written standard operating 
procedures which describe its strategies for tumour-specific therapy modalities 
covering: 
 How to generally discuss and decide with patients on their tumor-specific 
therapeutic strategies based on best evidence-based practices and their status 
as well as their needs and desires 
 How to select patients for specific thoracic surgical procedures and how to best 
perform these thoracic surgical procedures covering pre-, peri- and 
postoperative phase 
 How to select patients for specific systemic therapies including targeted 
therapies and immunotherapies and how to best perform these systemic 
therapies 
 How to select patients for specific radiotherapies and how to best perform 
these radiotherapies 
 How to select patients for multimodal therapies and how to best perform these 
multimodal therapies 
 
Multidisciplinary team play in the phase of tumour-specific therapies involves in 
particular thoracic surgery, oncology/pneumo-oncology, radiotherapy, pulmonology, 
radiology and pathology/molecular diagnostics – interdisciplinary interfaces must be 
described in written form within the named Standard operating procedures. 
Guideline 
ii. Thoracic Surgery  
Essential: The lung cancer service must provide or have access to the following 
thoracic surgical procedures: 
 Wedge resesction 
 Open segmentectomy 
 VATS-Segmentectomy 
 Open lobectomy 
 VATS-lobectomy 
 Pneumonectomy 
 Sleeve-lobectomy 
 Sleeve-pneumonectomy 
 Video-assisted mediastinoscopic lymphadenectomy (VAMLA) 
 
Complete lymph node dissection should be ensured in anatomical resections. 
Guideline 
Staff requirements: Thoracic surgery should be performed by specifically qualified 
and trained personnel (ordinarily, general thoracic surgeons and/or cardiothoracic 
surgeons and respective medical assistance personnel).  
 
Proof of individual experience could be furnished by a logbook, a personal catalogue 
of performed operations or similar measures. 
 
Anaesthetists specialised in narcosis in thoracic surgery and pain management, 
physiotherapists and intensive care professionals are in particular essential 
Good practice 
throughout the pre-, peri- and postoperative phases of patients undergoing thoracic 
surgery. 
 
Staff quantity should be sufficient. However, at present, a specific minimum number 
of staff cannot be justified. 
 
Institutional requirements: Thoracic surgery should be performed in dedicated 
general thoracic surgery services and/or cardiothoracic surgery services adequately 
covering the pre-, peri- and postoperative phases. 
 
Good practice 
Volume of care: At present, a specific minimum individual or institutional volume 
threshold for number of thoracic surgical procedures with prognostic relevance 
cannot be justified. 
 
Literature review and 
assessment 
Time standards: Thoracic surgery should be available daily in emergencies or urgent 
cases, otherwise within reasonable time.  
 
However, at present, a specific maximum time with prognostic relevance for 
performance of thoracic surgery cannot be justified. 
Good practice 
 
Literature review and 
assessment 
iii. Systemic Therapy  
Essential: The lung cancer service must provide or have access to the following types 
of systemic therapies or their combinations: 
 Chemotherapies 
 Targeted therapies 
 Immunotherapies 
 
The lung cancer service should be capable to offer systemic therapies on an out-
patient and in-patient basis. 
 
Guideline 
Staff requirements: Systemic therapies including targeted therapies and 
immunotherapies should be performed by specifically qualified and trained 
personnel (ordinarily, oncologists and/or pneumo-oncologists and respective 
medical assistance personnel).  
 
Staff quantity should be sufficient. However, at present, a specific minimum number 
of staff cannot be justified. 
 
Good practice 
Institutional requirements: Systemic therapies including targeted therapies and 
immunotherapies should be performed in dedicated oncology services and/or 
pulmonology services. 
 
Good practice 
Volume of care: At present, a specific minimum individual or institutional volume 
threshold for number of systemic therapies including targeted therapies and 
immunotherapies with prognostic relevance cannot be justified. 
 
Literature review and 
assessment 
Time standards: Systemic therapies including targeted therapies and 
immunotherapies should be available in reasonable time.  
 
However, at present, a specific maximum time with prognostic relevance for 
performance of systemic therapies including targeted therapies and 
immunotherapies cannot be justified. 
Good practice 
 
 
Literature review and 
assessment 
iv. Radiotherapy  
Essential: The lung cancer service must provide or have access to the following types 
of radiotherapy/radiotherapy techniques: 
 Stereotactic body radiotherapy 
 Intensity modulated radiotherapy (i.e. volumetric modulated arc therapy 
Guideline 
[VMAT]) 
 Motion management 
Staff requirements: Radiotherapy should be performed by specifically qualified and 
trained personnel (ordinarily, radiation-oncologists/clinical oncologists, 
radiotherapists and medical physicists). 
 
Staff quantity should be sufficient. However, at present, a specific minimum number 
of staff cannot be justified. 
 
Good practice 
Volume of care: At present, a specific minimum individual or institutional volume 
threshold for number of radiotherapies with prognostic relevance cannot be 
justified. 
 
Literature review and 
assessment 
Time standards: Radiotherapy should be available in reasonable time. 
However, at present, a specific maximum time with prognostic relevance for 
initiation of radiotherapy cannot be justified. 
Good practice 
 
Literature review and 
assessment 
v. Multimodal Therapy  
Essential: The lung cancer service must provide written standard operating 
procedures for treatment situations in which multidisciplinary discussion and 
consent finding as well as multimodal treatment in a multidisciplinary team are 
essential. Amongst others, examples are: 
 NSCLC, stage IA 
 NSCLC, stage IIIA 
 NSCLC, stage IIIB - Pancoast 
 NSCLC, oligometastatic lung cancer disease 
 SCLC, limited disease 
 
Guideline 
4. Re-Staging and Follow-up during and after Therapy  
Essential: The lung cancer service must define as a written standard operating 
procedure and apply validated tools for re-staging of patients under or after 
treatment (i.e. RECIST 1.1, iRECIST). 
 
The lung cancer service must define and apply as a written standard operating 
procedure a joint follow-up strategy during and after therapy taking into account 
therapy response as well as assessment of general patient status and tumour- and 
therapy-related side effects. This follow-up strategy should be coordinated among 
concerned disciplines and ensure that patients are not lost to follow-up through the 
lung cancer service. 
 
Guideline 
5. Management of Progressive Disease and Relapse  
Essential: The lung cancer service must define as a written standard operating 
procedure and apply a structured approach for the management of progressive 
disease and relapse to its patients based on best evidenced-based practices as well 
as their needs and preferences. 
 
Guideline 
6. End-of-life Care, Death and Bereavement Period  
Essential: The lung cancer service must define as a written standard operating 
procedure and apply a structured approach for the management of end-of-life care 
and death of a patient as well as for the support of carers throughout the 
bereavement period. 
 
Guideline 
7. Survivorship  
Essential: The lung cancer service must define as a written standard operating 
procedure and apply a structured approach for the management of patients who 
have achieved survivorship addressing amongst other things physical rehabilitation, 
Guideline 
psychological support, resilience and social reintegration. 
 
8. Cross-pathway Care  
i. Tumour- and Care-related Side Effect Management  
Essential: The lung cancer service  must provide written standard operating 
procedures on the management of the following tumour- and care related side 
effects: 
a) Tumour-related 
 Dyspnoea 
 Pain 
 Superior vena cava syndrome 
 Endotracheobronchial obstruction 
 Haemoptysis 
 Tracheobronchial-oesophageal fistula 
 Pleural effusion 
 Hoarseness 
 Cough 
 Fatigue 
 Bone metastases 
 Brain metastases 
 Spinal cord compression and neurological deficits 
 Cachexia/muscle wasting 
 Venous thromboembolic disease 
 Hypercalcaemia 
 Hyponatraemia/ syndrome of inappropriate antidiuretic hormone secretion 
(SIADH) 
 
b) Therapy-related 
 Post-thoracotomy pain 
 Pneumonia 
 Respiratory failure 
 Adverse cardiac events 
 Prolonged airleak 
 Bronchopleural fistula 
 Empyema 
 Pneumonitis/pulmonary fibrosis induced by radiotherapy or systemic therapies 
 Oesophagitis induced by radiotherapy or systemic therapies 
 Nausea/vomiting 
 Anaemia 
 Neutropenia 
 Thrombopenia 
 Dermatitis 
 Mucositis 
 Endocrinological disorders (i.e. hypophysitis, thyroiditis) 
 Allergic reactions or other autoimmune reactions 
 Extravasate  
 
Guideline 
ii. Emergency Care, Intensive Care  
Essential: The lung cancer service must provide or have access to an emergency care 
service for its patients as well as access to intensive care. 
 
The lung cancer service must define as a written standard operating procedure and 
apply a structured approach for the management of its lung cancer patients in case 
of medical emergencies taking into account best evidence-based practices as well as 
patient needs and preferences (i.e. potential pre-formulated limitations of 
Guideline 
therapeutic measures). 
 
Equally, the lung cancer service should offer psychological, social and spiritual 
support in case of respective crises. 
 
iii. Palliative Care  
Essential: The lung cancer service must provide or have access to a palliative care 
service for its patients seeking integration of palliative care throughout the entire 
lung cancer continuum depending on respective patient symptom load. 
 
Palliative care within the lung cancer service must include at least one of the 
following elements*: 
 Palliative care ward 
 In-patient palliative care liaison service  
 Out-patient palliative care liaison service 
 In-patient palliative care nurse 
 Out-patient palliative care nurse 
 Hospice 
 
*Collaboration with external palliative care services/hospices could be an alternative 
Guideline 
iv. Spiritual Care Service 
 
 
Essential: Depending on respective cultural habits, the lung cancer service should 
provide or have access to a spiritual care service for its patients. 
 
Good practice 
v. Specialised Nursing  
Essential: The lung cancer service should provide or have access to nursing 
specialised in lung cancer care for its patients. A nurse specialised in lung cancer care 
should have knowledge and understanding of the lung cancer pathway and 
treatments in order to facilitate support for patients and their carers. 
 
Advanced: The majority of patients should be seen by a specialised lung cancer 
nurse. 
 
Guideline 
vi. Physiotherapy and Rehabilitation  
Essential: The lung cancer service must provide or have access to a physiotherapy 
service for its patients. A collaboration with rehabilitation services should be sought. 
 
Patients after completion of first line therapy should be offered a disease-adequate 
rehabilitation measure. 
 
The lung cancer service must define as a written standard operating procedure and 
apply a structured multi-professional approach for the management of its lung 
cancer patients with the aim to achieve fitness for therapy with curative intent when 
potentially reversible causes have been identified in so far unfit patients. 
 
Guideline 
vii. Social Work Service  
Essential: The lung cancer service must provide or have access to a social work 
service for its patients. 
 
Every patient with a first diagnosis of lung cancer should be offered counselling by a 
social work service member or qualified professional. 
 
Guideline 
viii. Psychology Service  
Essential: The lung cancer service must provide or have access to a psychology 
service for its patients. 
Guideline 
 
Every patient with a first diagnosis of lung cancer should be offered counselling by a 
psychology service member or qualified professional (i.e. specialised lung cancer 
nurse). 
 
Advanced: The lung cancer service should apply a validated tool to systematically 
screen lung cancer patients for their psychological support needs. 
 
Supervision of multidisciplinary team services as well as individual burnout 
screening/prevention and support measures for professionals should be provided by 
the psychology service or other qualified professionally 
Good practice 
ix. Nutrition Counselling  
Essential: The lung cancer service must provide or have access to a nutrition 
counselling service for its patients. 
 
Guideline 
Advanced: The lung cancer service should apply a validated tool to systematically 
screen lung cancer patients for their nutritional status. 
 
Guideline 
x. Pain Management  
Essential: The lung cancer service must provide or have access to a pain 
management service for its patients. 
 
Guideline 
Advanced: The lung cancer service should apply a validated tool to systematically 
screen lung cancer patients for pain. 
 
Guideline 
xi. Smoking Cessation  
Essential: The lung cancer service must provide or have access to a smoking 
cessation programme for its patients. 
 
Guideline 
xii. Clinical Research   
Essential: Every patient with lung cancer should be considered for local, national or 
international trials. 
 
Advanced: The lung cancer service should provide or have access to a clinical 
research service for its patients. 
Good practice 
 
Glossary of terms used in the manual of lung cancer services 
 
Terminology used in the 
manual of lung cancer 
services 
Definition Other terminology 
Carer a family member or paid helper who regularly 
looks after a sick person 
 
Clinical cancer registry an information system designed for the 
collection, storage an analysis of epidemiological 
and clinical data on patients with cancer 
 
Clinical research a branch of science which explores efficacy and 
safety of medicines and other preventional, 
diagnostic or treatment regimens in patients  
 
Hospice “An inpatient hospice admits patients in their 
last phase of life, when treatment in a hospital is 
not necessary and care at home or in a nursing 
home is not possible.” [1] 
 
Lung cancer specialist a physician specialised in lung cancer  
Medical Oncology a medical discipline concerned with the 
prevention, diagnosis and treatment of cancer 
Oncology 
Medical physicists “an individual who is competent to 
independently provide clinical professional 
services in one or more of the subfields of 
medical physics. 
 Therapeutic Medical Physics 
 Diagnostic Medical Physics 
 Nuclear Medical Physics 
 Medical Health Physics 
 Magnetic Resonance Imaging Physics” [2] 
 
Nutrition counselling a service in which health professionals assess the 
dietary habits of individuals and provide 
qualified advice and information if change seems 
necessary 
 
Oncologist a physician specialised in medical oncology Medical oncologist 
Pain management a service in which health professionals assess the 
origin as well as the quality and quantity of pain 
in individuals and provide qualified advice, 
information and treatment modalities to 
overcome pain 
 
Palliative care “an approach that improves the quality of life of 
patients and their families facing the problems 
associated with life-threatening illness, through 
the prevention and relief of suffering by means 
of early identification and impeccable 
assessment and treatment of pain and other 
problems, physical, psychosocial and spiritual” 
[3] 
 
Pneumo-oncologist a physician specialised in pneumo-oncology  
Pneumo-oncology a medical sub-discipline concerned with the 
prevention, diagnosis and treatment of cancer in 
the field of pulmonology 
Thoracic oncology 
Psychology service a service in which health professionals provide 
mental health care for individuals and their 
carers 
 
Pulmonologist a physician specialised in pulmonology Chest physician 
Pneumologist 
Pulmonology a medical discipline concerned with the 
anatomy, physiology, and pathology of the lungs 
and airways 
Pneumology 
Respiratory care 
Radio-oncologist a physician specialised in radiotherapy Clinical oncologist 
Radiotherapist an allied health professional who works in the 
field of radiotherapy 
Radiation therapist 
Radiotherapy a medical discipline concerned with the 
treatment of diseases with radiation 
Radio-oncology 
Radiation oncology 
Social work service a service in which health professionals provide 
socio-legal counselling, concerning 
reorganisation of occupational matters, securing 
of financial integrity as well as care and supply 
needs, and psychosocial counselling, addressing 
emotional needs and support, stigma, coping 
strategies, understanding of new/altered roles 
and relationships, and importance of social 
networks 
 
Specialised lung cancer 
nurse 
a nurse who has knowledge and understanding 
of the lung cancer pathway and treatments 
facilitating support for patients and their carers 
 
Spiritual care service a service in which health professionals provide 
mental health care for individuals and their 
carers 
 
Thoracic surgeon a physician specialised in thoracic surgery  
Thoracic surgery a medical discipline concerned with prevention, 
diagnostics, surgical treatment of diseases, 
malformations and injuries of the lung, bronchi, 
pleura, mediastinum and chest wall as well as 
the adjacent parts of the heart  
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Underlying evidence for lung cancer service parameter catalogue 
 
Part of Lung Cancer Care 
Pathway 
Chapter Evidence 
Initial assessment II.1.ii. ACCP [68], German lung cancer guideline [69], NICE [70] 
Functional Assessment, 
Appraisal of Fitness for 
Diagnostics and Therapy 
II.1.iii. ACCP [71], BTS [72], ESTS/ERS [54], German lung cancer 
guideline [69], NICE [70] 
Imaging II.1.iv. ACCP [73], ESR/ACR [53], German lung cancer guideline [69], 
NICE [70] 
Endoscopy II.1.v. ACCP [73, 74], BTS[75], ESGE/ERS/ESTS [76], German lung 
cancer guideline [69], NICE [70], WABIP [77] 
Percutaneous Image-guided 
Biopsy Procedures 
II.1.vi. ACCP [73, 74], German lung cancer guideline [69], NICE [70] 
Mediastinoscopy II.1.vii. ACCP [73, 74], German lung cancer guideline [69], NICE [70] 
Medical Thoracoscopy, Video-
assisted Thoracoscopy (VATS) 
II.1.viii. ACCP [73, 74], German lung cancer guideline [69], NICE [70] 
Tissue-based Tumour Sampling 
Biofluid-based Tumour 
Sampling 
Pathology and Molecular 
Diagnostics  
II.1.ix. 
II.1.x. 
II.1.xi. 
ACCP [73, 74], German lung cancer guideline [69], IASLC [78], 
NICE [70], WHO [79] 
TNM Description and Stage 
Grouping 
II.1.xii. IASLC [80-85], UICC [86] 
Medical Decision-finding and 
Care Planning with Patients and 
within the Multidisciplinary 
Team 
II.2. German lung cancer guideline [69], NICE [70] 
Core Strategies for Tumour-
specific Therapy 
II.3.i. BTS [72], German lung cancer guideline [69], NICE [70] 
Thoracic Surgery II.3.ii. BTS [72], ESTS [55], German lung cancer guideline [69], NICE 
[70] 
Systemic Therapy II.3.iii. ESMO [87-89], German lung cancer guideline [69], NICE [70] 
Radiotherapy II.3.iv. BTS [72], EORTC [62], ESTRO/ACROP [64], German lung cancer 
guideline [69], NICE [70] 
Multimodal Therapy II.3.v. BTS [72], German lung cancer guideline [69], NICE [70] 
Re-Staging and Follow-up 
during and after Therapy 
II.4. German lung cancer guideline [69], iRECIST [90], NICE [70], 
RECIST [80] 
Management of Progressive 
Disease and Relapse 
II.5. German lung cancer guideline [69], NICE [70] 
End-of-life Care, Death and 
Bereavement Period 
II.6. EAPC [65], German lung cancer guideline [69], NICE [70] 
Survivorship II.7. German lung cancer guideline [69], NICE [70] 
Cross-pathway Care II.8. EAPC [65], German lung cancer guideline [69], NICE [70] 
Legend: ACCP: American College of Chest Physicians, ACR: American College of Radiology, ACROP: Advisory 
Committee on Radiation Oncology Practice, BTS: British Thoracic Society, EAPC: European Association for 
Palliative Care, EORTC: European Organisation for Research and Treatment of Cancer, ERS: European 
Respiratory Society, ESGE: European Society of Gastrointestinal Endoscopy, ESMO: European Society for 
Medical Oncology, ESR: European Society of Radiology, ESTRO: European Society for Radiotherapy and 
Oncology, ESTS: European Society of Thoracic Surgeons, IASLC: International Association for the Study of Lung 
Cancer, NICE: National Institute for Health and Care Excellence, UICC: Union Internationale Contre le Cancer, 
WABIP: World Association for Bronchology Interventional Pulmonology
Supplement 3 
 
Supplement 3.1: Existing datasets of Lung Cancer Registration 
 
Dataset Author Comments 
Cancer Outcomes 
and Service Dataset 
(COSD) 
Began January 2013 
National Cancer 
Registration and 
Analysis Service; 
Public Health 
England 
(previously known 
as the National 
Cancer Intelligence 
Network) 
Data definitions for data collection for all 
cancers at national level. Some fields are 
generic for all cancer sites, others are 
tumour specific.  Mandatory for all providers 
of cancer care to submit data on a monthly 
basis to COSD. 
Managed by the National Cancer 
Registration and Analysis Service (NCRAS) 
which can integrate these data with a 
number of other data feeds, including 
Hospital Episode Statistics (HES), the 
Systemic Anti-Cancer dataset (SACT) derived 
from electronic prescribing, the 
Radiotherapy Treatment Dataset (RTDS) 
taken from the radiotherapy treatment 
machines (Linear Accelerators) and NHS 
Digital’s Diagnostic Imaging Dataset. 
http://www.ncin.org.uk/collecting_and_using_data/data_collection/cosd_downloads_v7  
 
Danish Lung Cancer 
Registry 
 V4.1 October 2015 
https://www.rkkp-dokumentation.dk/Public/Databases.aspx 
 
European Network 
for Cancer 
Registration (ENCR) 
International 
Agency for Research 
on Cancer (IARC) 
Recommendations for a Standard Dataset 
for the European Network of Cancer 
Registries published in 2005. 
Aimed to preserve the possibility for 
comparison between European Registries 
and rest of world and to promote wide-scale 
collaboration across Europe.   
http://www.encr.eu/images/docs/recommendations/recommendations.pdf 
 
International 
Consortium for 
Health Outcomes 
Measurement 
(ICHOM) 
Lung Cancer data 
collection Reference 
 Version 2.1 revised April 2015. 
Collaboration of patient representatives, 
clinicians and registry leaders from across 
the world, who have designed a dataset of 
outcome measures and case-mix variables 
specific for lung cancer. The aim is to use a 
standardised set of outcome measures to 
Guide compare performance, encourage sharing of 
best practice, and improve the care provided 
to our patients. 
http://www.ichom.org/ 
 
German Lung cancer 
parameters 
§ The standardized oncological basic dataset 
of ADT and GEKID was adopted in March 
2008 and updated in February 2014. It 
applies to all cancers and is continuously 
supplemented with tumour-specific 
modules. With the standardized basic 
oncological dataset, an instrument has been 
created which sets a uniform oncological 
standard, prevents multiple documentation 
and enables comparable recording and 
evaluation of cancer treatments in all federal 
states and clinical structures in Germany. 
http://www.tumorzentren.de/tl_files/dokumente/Module%20zum%20Basisdatensatz/Bund
esanzeiger_BDS_28.04.14.pdf 
 
 
Supplement 3.2:  An example of coding for ethnicity 
 
Office of National Statistics (ONS) UK. 
 
Code Ethnicity 
White  
A British 
B Irish 
C Any other White background 
Mixed  
D White and Black Caribbean 
E White and Black African 
F White and Asian 
G Any other mixed background 
Asian or Asian British  
H Indian 
J Pakistani 
K Bangladeshi 
L Any other Asian background 
Black or Black British  
M Caribbean 
N African 
P Any other Black background 
Other ethnic Groups  
R Chinese 
S Any other ethnic group 
  
Z Not stated 
 
Supplement 3.3: Results of narrative evidence search on websites of international societies and other 
stakeholders related to lung cancer care as well as those on the national level accessible by taskforce members 
 
Name of society/stakeholder Website Results 
International societies 
European Association for 
Palliative Care (EAPC) 
www.eapcnet.eu 
 
White Paper on standards and 
norms for hospice and 
palliative care in Europe: part 
1+2 [1] 
European Lung Foundation www.europeanlung.org Patient priorities project lung 
cancer [2]  
European Organisation for 
Research and Treatment of 
Cancer (EORTC) 
www.eortc.org 
 
European Organization for 
Research and Treatment of 
Cancer (EORTC) 
recommendations for planning 
and delivery of high-dose, high 
precision radiotherapy for lung 
cancer [3] 
European Respiratory Society www.ersnet.org Thoracic Oncology HERMES [4-
6] 
European Society for Medical 
Oncology (ESMO) 
www.esmo.org 
 
Designated Center of 
Integrated Oncology and 
Palliative Care Application [7] 
European Society for 
Radiotherapy and Oncology 
 
Advisory Committee on 
Radiation Oncology Practice 
(ACROP) 
www.estro.org 
 
ESTRO ACROP consensus 
guideline on implementation 
and practice of stereotactic 
body radiotherapy for 
peripherally located early stage 
non-small cell lung cancer [8] 
European Society of Radiology 
(ESR) 
www.myesr.org 
 
European Society of Radiology 
(ESR) and American College of 
Radiology (ACR) report of the 
2015 global summit on 
radiological quality and safety 
[9] 
European Society of Thoracic 
Surgeons (ESTS) 
www.ests.org 
 
Clinical guidelines for 
evaluating fitness for radical 
treatment (surgery and 
chemoradiotherapy) in 
patients with lung cancer (with 
ERS) [10] 
 
European guidelines on 
structure and qualification of 
general thoracic surgery [11] 
International Association for the 
Study of Lung Cancer (IASLC) 
www.iaslc.org 
 
Adenocarcinoma classification 
[12] 
 
Lung cancer staging 
recommendations [13-18] 
Organisation of European 
Cancer Institutes 
www.oeci.eu 
 
OECI Accreditation and 
Designation [19] 
Union Internationale Contre le 
Cancer (UICC) 
www.uicc.org 
 
Lung cancer staging 
recommendations [20] 
World Association for www.wabip.com  
Bronchology Interventional 
Pulmonology (WABIP) 
 
Other International Stakeholders 
European Union www.europa.eu 
 
Project cycle management [21] 
World Health Organization www.who.int 
 
WHO classification of tumours 
of the lung [22] 
 
Definition of Palliative Care 
[23] 
National societies/other stakeholders 
-Germany 
Deutsche Gesellschaft für 
Hämatologie und Medizinische 
Onkologie 
www.dgho.de 
 
Onkologisches Zentrum 
(Oncologic Centres) [24] 
Deutsche Gesellschaft für 
Pneumologie und 
Beatmungsmedizin (German 
Respiratory Society) 
www.pneumologie.de 
 
German lung cancer guideline 
[25] 
Deutsche Gesellschaft für 
Thoraxchirurgie (German 
Society for Thoracic Surgery) 
www.dgt-online.de 
 
Kompetenzzentrum 
Thoraxchirurgie (Certification 
of Thoracic Centres) [26] 
Deutsche Krebsgesellschaft 
(German Cancer Society) 
 
Onkozert 
www.dkg.de 
 
 
www.onkozert.de 
Lungenkrebszentren 
(Certification of lung cancer 
centres) [27, 28] 
-United Kingdom 
British Thoracic Society www.brit-thoracic.org.uk 
 
Guideline for diagnostic flexible 
bronchoscopy in adults [29] 
 
Guideline on radical 
management of patients with 
lung cancer [30] 
Cancer Research UK www.cancerresearchuk.org 
 
 
Lung Clinical Expert Group: 
National Optimal Lung Cancer 
Pathway [31] 
 
Lung Cancer Centres of 
Excellence [32] 
Expert Advisory Group on 
Cancer to the Chief Medical 
Officers of England and Wales 
 A Policy Framework for 
Commissioning Cancer Services 
[33] 
National Institute for Health and 
Care Excellence 
www.nice.org.uk NICE guideline on the Diagnosis 
and Treatment of Lung Cancer 
(Update) [34] 
-United States of America 
American College of Chest 
Physicians (ACCP) 
www.chestnet.org 
 
ACCP guideline on diagnosis 
and management of lung 
cancer, 3rd edition 
Bonnie J. Addario Lung Cancer 
Foundation 
www.lungcancerfoundation.org Centers of Excellence [35] 
National Cancer Institute www.cancer.gov 
 
NCI-Designated Cancer Centers 
[36] 
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